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From Antimicrobial Activity to Zinc Binding: An in-depth Analysis of the
Tunicate Host Defense Peptide Clavanin A
Samuel A. Juliano IV, PhD
The University of Connecticut, 2020
Due to the overuse of conventional antibiotics, coupled with the slow rate of development
of novel treatments, antibiotic resistant bacteria have been on the rise. Antimicrobial peptides
(AMPs), especially those that bind to biologically relevant metal cations, present an excellent
source of potential antibacterial compounds with a low incidence of resistance development. This
dissertation explores one such metal binding AMP, the tunicate peptide clavanin A. In the past,
clavanin A has been fairly well studied for its activity against the bacterial membrane; however, a
fortuitous discovery led us to study clavanin A in the presence of metal ions. We discovered that,
in the presence of Zn2+ ions, clavanin A is capable of cleaving bacterial chromosomal DNA, an
activity never before reported for a zinc binding AMP. This mechanism of action also has the
benefit of improving the antibacterial activity of clavanin A 16-fold. These promising results led
to the exploration of AMP mechanisms of action through the application of bacterial cytological
profiling. Our study represents the first use of this technique for the study of AMPs. Bacterial
cytological profiling allowed us to identify that clavanin A has three distinct mechanisms of action:
a membrane-based mechanism at neutral pH that is similar to that of the piscidin peptides, another
membrane-based activity at low pH involving strong membrane interaction, and the zinc-based
nuclease activity discussed above. The results presented in this dissertation combine to show that
not only is clavanin A an interesting AMP system for study, but it is also a prime candidate for the
modifications necessary to develop novel peptide-based antibiotic treatments to fend off antibiotic
resistant bacteria.
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Chapter 1 – Introduction: On the Shoulders of Giants

“If I have seen further it is by standing on the shoulders of Giants.”
-Sir Isaac Newton, 1675
“Everyone shush now…I’m about to be impressive.”
-Sebastien de Castell, Tyrant’s Throne

1.1 – The Problem: Antibiotic Resistance
While many people may look to climate change, war, and cancer as the biggest threats
mankind will face over the next thirty years, one problem grows silently, year after year, without
much public recognition. Antibiotic resistant bacteria represent a significant threat to the health
and wellbeing of mankind, so much so that the World Health Organization lists it as one of its
top ten threats to global public health.1 In 2013, the Centers for Disease Control reported that
over 2 million individuals were infected with antibiotic resistant infections, resulting in the
deaths of about 23,000 people in the United States alone.2 In the last six years these numbers
have increased dramatically such that nearly 3 million incidences of infection occur, leading to
over 35,000 deaths.3 In Europe, the European Center for Disease Prevention and Control reports
33,000 annual deaths in the EU due to these difficult to treat infections.4 The situation in
developing nations is even worse, with 88% of Nigerian Staphylococcus aureus infections
resistant to methicillin, and 95% of Indian adults carrying β-lactam resistant bacteria (compared
with about 10% for New York City).5 The World Health Organization claims that the world is
poised to enter a “post-antibiotic era” unless something is done to stem the tide.6 Some
frightening projections estimate that by 2050, the death toll will reach over 2.4 million
individuals with costs in excess of $3 billion per year.7
While it is certainly necessary to develop new antimicrobial treatments that are less likely
to develop resistance, it is also important to be aware of the factors that lead to resistance in the
first place. In his 1945 Nobel Lecture, Alexander Fleming predicted the possibility of bacterial
resistance to penicillin, stating “It is not difficult to make microbes resistant to penicillin in the
laboratory by exposing them to concentrations not sufficient to kill them…”8 He then concludes
his lecture with the admonition “If you use penicillin, use enough.” Even in the earliest days of
2

antibiotics it was known that people will often stop taking their medication because they no
longer experience the symptoms that lead them to turn to antibiotics in the first-place, resulting
in under-dosed bacterial pathogens. This is one of the leading causes of antimicrobial resistance
today, though far from the only one. Figure 1-1 shows a representation of how antibiotic
resistance occurs and spreads.

Figure 1-1
The development of antibiotic resistance: 1) A person or animal becomes infected with a bacterial
infection. A small portion of those bacteria are resistant (orange). 2) The patient is treated with an
antibiotic, killing all of the non-resistant bacteria, often including the host’s beneficial bacteria,
and sparing the resistant bacteria. 3) The patient stops taking their antibiotic, allowing the bacteria
to repopulate. The proportion of resistant bacteria is now greater, increasing the likelihood of
transmission of resistant pathogens. 4) Resistance can be transmitted to non-resistant bacteria
through horizontal gene transfer.

While Fleming assumed there was no danger in antibiotic overuse, we have learned in the
years since his discovery that this is not the case. In developing countries, in particular, antibiotic
use is largely unrestricted, with many countries selling antibiotics as over the counter
treatments.9 This availability results in sick individuals self-medicating with antibiotics, even for
conditions that do not require them, such as viral infections or malaria. In other countries, such
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as China, healthcare providers and hospitals are provided with financial incentives for each
antibiotic prescription written, resulting in cases of gross over-prescription.5
Aside from antibiotic use and abuse in humans and natural mutations, one of the largest
sources of antibiotic resistance mutations to bacteria is the use of antibiotics on animals,
typically in an agricultural setting. Commercially farmed animals, including cows, chickens,
sheep, and pigs, are often dosed with continuous, subtherapeutic quantities of antibiotic in order
to promote growth and prevent disease.10 In the US alone this amounts to over 13 million
kilograms of antibiotics annually, a whopping 80% of the antibiotic use for the country.11 Much
like in humans who under-dose their bacterial infections, the application of subtherapeutic
concentrations of antibiotics in these animals has led to the development of a large reservoir of
antibiotic resistant bacteria (Figure 1-1). These bacteria can then be transferred to humans
through the direct transfer of bacteria via contact with the animals, improperly handled meat, or
materials contaminated with feces. Antibiotic resistance can also arise in bacterial populations
through horizontal gene transfer from bacteria specific to livestock to those that can infect
humans.12
In developed nations the most common means to acquire an antibiotic resistant infection
is through hospital acquired, or nosocomial, infection. These infections are responsible for the
deaths of over 1 million patients annually in the US, many of which come from antibiotic
resistant bacteria. The most prevalent offenders when it comes to nosocomial infections are the
so called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).13,
14

A growing number of isolates of these bacteria collected from hospitals and doctor’s offices

contain antibiotic resistance genes, which is largely to account for the increased mortality
4

reported above.15 Of particular interest are the gram negative members of this group, as they are
more difficult to kill than gram positive bacteria due to their outer membranes and efflux pumps
(Figure 1-2).16, 17 Several isolates of Acinetobacter spp. and Pseudomonas spp. have been
identified that have resistance genes to all known classes of antibiotics.18 Additionally, Klebsiella
derived carbapenem resistance genes isolated in India have been found in various species of
bacteria world-wide, highlighting the dangers of horizontal gene transfer.19 With so many
bacteria showing resistance, even to some of the antibiotics of last resort, the need for novel
therapeutic compounds to combat the problem is greater than ever.

5

Figure 1-2
Representative of gram-positive and gram-negative cell walls. The outer most layer of a grampositive bacteria (left) is a cell wall composed of peptidoglycan (blue and green), followed by
the cytoplasmic membrane (yellow). Gram-negative cells (right) are surrounded by a layer of
lipopolysaccharide (purple) embedded in the outer membrane (yellow). The outer membrane
contains efflux pumps (red) which can remove antibiotics and AMPs from the periplasmic
space (gray), which contains the peptidoglycan cell wall (blue and green). The final layer of
defense for a gram-negative cell is the inner (cytoplasmic) membrane (yellow).

All of this information points to the need for the development of new, more potent
antimicrobials. The current antibiotic development paradigm, the modification of current small
molecule antibiotics to overcome resistance mechanisms is falling behind the ability of bacteria
to mutate resistance genes.20, 21 The three qualities that should be sought for when considering
new molecules as novel antibiotics are i) localized targeting with minimal interaction with host
tissue, ii) low incidence of resistance development, and iii) protecting native flora whenever
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possible (Figure 1-3).12 The current generation of antibiotics based on small molecules is capable
of meeting the former criteria, but fails miserably with regard to the latter two.

Figure 1-3
Conceptual diagram outlining the three criteria (left) necessary for any strategy designed to
circumvent the recognized modes of antibiotic resistance (right). Figure repurposed from
reference 12.
1.2 – Antimicrobial peptides/Host defense peptides
Many of the antibiotics we utilize today are derived from natural small molecules
produced by a wide variety of organisms in order to defend themselves from infection by
bacterial pathogens. The major example of this is the antibiotic penicillin, which was isolated
from the penicillium mold in the late 1920s.22 Since then, several antibiotics have been
synthesized based on the structure of this influential molecule, including ampicillin, amoxicillin
and methicillin.23-25 Entire classes of antibiotics only exist because of discoveries made studying
the natural defenses of various organisms. The aminoglycosides were first discovered in 1943
7

with the isolation of streptomycin from the soil bacteria Streptomyces griseus.26 This discovery
lead to the isolation of many more compounds with potent antimicrobial activity, including
kanamycin, erythromycin and vancomycin. Our past reliance on molecules originating from
natural sources can inform a solution to the current predicament of antibiotic resistant bacteria.
We should be returning to natural systems as a means to develop new treatments to stop the
growing scourge.
Antimicrobial peptides (AMPs) represent a large and particularly effective pool of
molecules with potent antimicrobial activity that we could utilize in order to develop novel
means to combat bacterial infections. These evolutionarily ancient molecules can be found as
innate immune components across nearly all domains of life, earning them the moniker host
defense peptides (HDPs).27, 28 For the most part, AMPs are short, cationic peptide sequences, 1050 amino acids in length, which challenge invading bacteria either through membrane disruption
or the targeting of intracellular macromolecules like DNA.29 The majority of AMPs discovered
form amphipathic α-helices, with hydrophobic and hydrophilic residues on opposite faces of the
helix, though other secondary structures have been observed including β-sheets and intrinsically
disordered structures (Figure 1-4).30
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Figure 1-4
Structures of several (a) α-helical, (b) β-sheet, and (c) random coil AMPs. Figure repurposed
from reference 29.

The vast majority of AMPs are broad spectrum, exhibiting potent antimicrobial activity
against gram-negative and gram-positive bacteria. Their ability to target bacteria rather than host
cells has been attributed to electrostatic interactions between the cationic peptide and the anionic
bacterial membrane.30 Eukaryotic cells more often contain zwitterionic membrane components,
decreasing the interaction between their membranes and AMPs. Once an AMP interacts with the
membrane, many will exert antimicrobial activity through disruption of the membrane, resulting
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in leakage of cellular components or disruption of fundamental ion gradients. Several AMPs
have also been discovered that will pass through the membrane via non-lytic means and instead
target internal components, such as DNA or ribosomes. A growing group of AMPs have been
identified which are capable of exerting antimicrobial activity via more than one mechanism.31
These multi-hit AMPs are particularly interesting as they present the best means for the
development of novel antibiotics with reduced resistance development, as target promiscuity
would require bacteria to acquire multiple mutations in order to be able to survive all possible
AMP mechanisms of action. In addition, many of the targets for AMPs are nonspecific (e.g.
targeting membrane phospholipids rather than a specific protein) making the evolution of
bacterial resistance to AMPs even less likely. It should be noted, however, that while typical
bacterial antibiotic resistance mechanisms are ineffective against AMPs, it is possible for
bacteria to develop resistance to AMPs through the expression of efflux pumps and proteases,
though these methods often require more generations to develop relative to small molecule
resistance mechanisms.32, 33
Due to the advantageous nature of AMPs as potential novel therapeutic compounds,
several natural and naturally derived AMPs have made it to clinical and preclinical trials.34
Outside of AMPs and HDPs, peptides have gained FDA approval for the treatment of some
cancers and metabolic diseases, paving the way for a future with clinically available AMPs to
treat bacterial infections, though currently daptomycin (Figure 1-5A) is the only FDA approved
AMP.35 As of May 2019, 27 AMPs are being tested in clinical trials, with six in phase I, fifteen
in phase II, and a promising six in phase III trials (Figure 1-5B).34 Of the AMPs in phase three
trials, the vast majority are either synthetic analogs of naturally occurring AMPs or AMPs
designed to have a certain function, with only one, ramoplanin, that is natural.
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Figure 1-5
(A) Structure of the clinically approved AMP antibiotic, Daptomycin; (B) Status of AMPs
in clinical trials. Adapted from reference 34.

While AMPs and HDPs seem to be exactly what the doctor ordered in terms of a
replacement for the current generation of antimicrobials, there are some fairly significant
drawbacks to their use in their current form. In addition to the slow development of resistance
mentioned above, some AMPs show activities that are sensitive to varied conditions of pH or salt
concentrations due to the need for electrostatic interactions between the cationic peptides and the
anionic membrane.36, 37 Additionally, the presence of serum proteins can present issues due to
AMP inactivation as a result of protein binding.38 However, the largest drawback to the
utilization of AMPs in a clinical setting is the low in vivo stability often observed for AMPs. Due
to the presence of proteases and peptidases, AMPs are rapidly degraded in the blood-stream and
mucosa, and they are unable to survive harsh conditions found in the stomach.39, 40 While
alternate routes of administration are available (e.g. intravenous or intramuscular injections), for
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the most part, topical applications are explored in order to deal with these limitations. On top of
all of these limitations, peptides cost significantly more to produce than conventional small
molecule antibiotics, though new production methods are in development with the aim of
reducing costs.41
Despite the fact that all of these limitations seem to signal the death knell for AMPs as
clinically available antibiotics, there are several strategies that can be employed to overcome
these deficiencies. Many of the AMPs in clinical trials contain chemical modifications, which are
far and away the most commonly employed strategies for improving in vivo survival of AMPs.12,
42-45

The chemical modifications employed by AMPs in clinical trials include partial or complete

replacement of L-amino acids with their D counterparts, macrocyclization and incorporation of
noncanonical amino acids.34 Each of these modifications increases stability in vivo by decreasing
the rate of proteolysis. Larger modifications are also being explored, including glycosylation,
lipidation and halogenation. Other options for increasing stability include the utilization of
peptidomimetics, such as peptoids, β-peptides, and peptide-peptoid hybrids (Figure 1-6).46
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Figure 1-6
Structure of peptoids, with R groups found on backbone nitrogen instead of carbon, and βpeptides, with an extra backbone carbon in each amino acid.

The development of peptide based or peptide derived novel antimicrobial compounds
requires a strong understanding of what it is exactly about an AMP that makes it function the
way it does. For small molecule antibiotics, there are only so many positions that can be
modified, thus limiting the number of possibilities for more active modifications. This, coupled
with the relative ease by which crystal structures of these molecules bound to their target can be
obtained, makes modification of small molecules a relatively targeted process. On the other
hand, AMPs have between 10 and 50 amino acids, each of which can contribute different
properties depending on their location relative to other residues. It is important to have a wellstudied AMP from which to derive novel treatments. For example, two AMPs in clinical trials,
omiganan and pexiganan are derived from indolicidin and magainin 2, respectively, each of
which has been studied in over 200 publications. A greater understanding of a larger variety
AMPs is necessary in order for them to serve as templates for further antibiotic development.
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1.3 – Strategies of Metal Binding Host Defense Peptides
Metal ions are ubiquitous in biological systems, and this holds true for HDPs as well.
Many HDPs can bind to metal ions for a variety of reasons, including metal sequestration, metal
activation, and redox chemistry. The vast majority of these metal ion binding peptides utilize
multiple histidine residues as part of their binding motif.
Organisms will utilize metal sequestration in order to limit bacterial access to essential
micronutrients or metal ions necessary for virulence factors.47, 48 Bacterial hosts can excrete
metal binding HDPs, including microplusin, and the S100 peptides psoriasin and calprotectin,
which can sequester essential metal ions, limiting bacterial growth in order for the host to
eliminate the infection. Microplusin is found in several locations within ticks, and is composed
of five α-helical domains with disordered C- and N-termini.49-51 While the exact binding site has
not been identified, microplusin exerts its activity against gram positive bacteria as well as fungi
through sequestration of Cu2+ ions essential for cellular respiration and other bacterial
processes.51 S100 proteins have been known for many years to bind Ca2+ and activate the
immune response in mammals, though more recently, they have also been discovered to
sequester essential metal ions from bacterial infections.52 Psoriasin, an S100 peptide found on
human skin, has been found to contain a Zn2+ binding motif containing three histidines and an
aspartate.53 When pre-incubated with Zn2+, psoriasin loses its potency against E. coli, pointing to
sequestration as its primary mechanism of action.54 Another S100 peptide, calprotectin, goes one
step further, sequestering not only Zn2+ but also Mn2+. This sequestration activity not only serves
to deny microbes of essential metallic micronutrients, but also increases stability against
proteolysis, a common issue for AMPs.55-57
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While metal sequestering HDPs gain their antimicrobial activity from denying bacteria
access to micronutrients, HDPs that require metal activation are only useful when bacteria are
exposed to the peptide in the metallated state. It is commonly believed that binding metal
cofactors allows these HDPs to adopt a favorable conformation for binding to their bacterial
targets.58 Bacitracin A (Figure 1-7A), produced by several Bacillus species, can bind to a variety
of metal ions including Zn2+, Mn2+ and Na+.59, 60 Metal binding allows for bacitracin A to inhibit
cell wall biosynthesis by binding to undecaprenyl pyrophosphate.61 Dermcidin is an HDP
secreted in sweat glands which is proteolytically cleaved to the active form DCD-1.62 Crystal
structures of DCD-1 (Figure 1-7B) show that, in the presence of Zn2+ ions, it forms antiparallel
dimers, stabilized by the zinc ions. The dimers then form a trimer in a cylindrical pattern,
allowing for the formation of a transmembrane ion channel, though the means by which this
channel inserts into the membrane remains unknown.63, 64 The acidic conditions and high Zn2+
concentrations found in sweat allow DCD-1 to bind Zn2+ and oligomerize in order to kill
bacteria.
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Figure 1-7
Crystal structures of metal-bound (A) Bacitracin A, and (B) DCD-1.

Beyond the structural and electrostatic benefits of metal binding, HDPs have also been
shown to utilize metal ions for their ability to participate in redox reactions which can oxidize
bacterial components. The HDPs that utilize the redox properties of metals do so through
binding Cu2+ with the amino terminal copper and nickel (ATCUN) binding motif (Figure 1-8),
comprised of any two amino acids (with the exception of proline) followed by a histidine in the
third position. This motif, discovered in serum albumins, allows for the binding of Cu2+ in a
modified square planar arrangement utilizing the terminal nitrogen, the next two backbone
nitrogens and the unprotonated histidine nitrogen.65 In addition to ATCUN proteins, many HDPs
also utilize this motif for its oxidative ability when bound to Cu2+, including several histatins,
ixosin, and piscidins 1 and 3. Both histatin 3 and histatin 5 can bind to Cu2+ through their
ATCUN motifs, using Fenton-like chemistry to generate reactive oxygen species (ROS).66, 67
These peptides can also bind to Zn2+ utilizing an HEXXH motif, though it is unknown what
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effect this binding has on the antimicrobial activity.66 Ixosin, found in the salivary glands of
several tick species, utilizes its GLH ATCUN motif in order to oxidize membrane
phospholipids.68, 69 This oxidation allows for synergism with the closely related HDP ixosin B.68
The piscidin family of HDPs, found in fish mast cells, were originally believed to exert their
antimicrobial activity on bacterial membranes.70, 71 More recently, ATCUN containing piscidin 1
and piscidin 3 were found to act on both the membrane and DNA as an intracellular target,
though piscidin 1 favored the membrane while piscidin 3 acted more strongly against DNA.72
Both peptides utilize their ATCUN motifs for this activity, with H3A mutations drastically
reducing their activity. In addition to cleaving DNA intracellularly, piscidin 3 was found to
cleave extracellular DNA, disrupting the formation of biofilms.73

Figure 1-8
The ATCUN motif with a bound Cu2+ atom.
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1.4 – Tunicates and the metal-rich marine environment
Due in part to both natural sources and human activity, sea water presents a large source
of available metal ions, especially in regions near harbors and marinas. The Sea Urchins for
Education group at Stanford University report iron, copper and zinc to be among the most
abundant transition metals found in the oceans surrounding the US.74
As seen with the piscidins, marine life presents an excellent resource for the discovery of
novel AMPs with the ability to utilize these ubiquitous metal ions. Unlike land animals, marine
animals are constantly surrounded by concentrations of dissolved metals and minerals which
either need to be sequestered, so as not to harm the organism in question, or otherwise enriched
in order to promote some vital function. HDPs are a part of the innate immune system of many
lower organisms which lack adaptive immunity found in higher order creatures. Tunicates
provide an interesting organism for HDP study because their lack of an adaptive immune system,
despite being members of the phylum chordata, to which all vertebrates belong. There is much
interest in studying the fairly primitive immune system of tunicates as a means to understand
how more complex immune systems, such as our own, came to be.75, 76
As previously mentioned, tunicates are members of the phylum chordata, despite being
invertebrates, due to the fact that in their early development stages they contain features linked to
all chordates, including a notochord, pharyngeal gill slits and a post-anal tail (Figure 1-9A).
Tunicates start life a free swimming, tadpole-like organisms, though after metamorphosis they
become sessile filter-feeders, not unlike sponges (Figure 1-9B).77 One offshoot of
metamorphosing into a sessile form is that they become unable to change their local
environment, meaning that they need to adapt to the dissolved metal concentrations in their local
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environment rather than being able to leave the area. With respect to metal ions, this means that
tunicates can either sequester and excrete these ions, or employ them as a part of their regular
function, including utilizing them for host defense in conjunction with HDPs. In the tunicate
Styela clava zinc concentrations have been reported to be 26.7±7.1 μM, which amounts to
roughly two orders of magnitude enrichment over the surrounding seawater.74, 78 This organism,
then, presents an excellent opportunity for the discovery of metal-binding HDPs as a component
of its innate immune system.

Figure 1-9
Anatomy of (A) a planktonic tunicate larva, and (B) a sessile adult tunicate. Images
courtesy of Jon Houseman.
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1.5 – Clavanin A and the Clavanins
The clavanin family of cationic, α-helical HDPs was discovered in the hemocytes
(analogues of red and white blood cells found in invertebrates) of S. clava.79 The family contains
five members with about 80% sequence homology, and a sixth member with only ~50%
similarity that was discovered through the homology of the prepropeptide region of its genome
(sequences in Table 1-1.79-81 Clavanin A is by far the most studied member of the family,
appearing in at least 15 publications across five different laboratories, while each of the other
members of the family have only appeared in the publication in which they were first
presented.78, 79, 82-84 Clavanin B is nearly identical to clavanin A, with the only difference being
an arginine in place of a lysine at position 7, though this is a conserved mutation as both residues
are positively charged at biologically relevant pH values. Clavanins C and D were discovered to
be the most active members of the clavanin family against not only gram-negative and grampositive bacteria, but also fungi as well. Despite this potency and broad spectrum activity, these
HDPs have never been studied in depth, likely due to the modified tyrosine residue in the
sequence, which was originally believed to be a methyl-tyrosine, though the discovery of the
styelin family of peptides has indicated that the modified tyrosine may actually be a
dihydroxyphenylalanine (DOPA) residue.79, 85 Additionally, clavanin C contains an ATCUN
motif which is likely capable of binding Cu2+ and forming ROS, though this activity has never
been explored. Clavanin E and clavaspirin were not discovered in the initial clavanin study,
instead appearing as a result of exploration into the S. clava genome.80, 81
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Table 1-1

Sequences of the clavanin family of HDPs
Peptide

Sequence

Clavanin A79

VFQFLGKIIHHVGNFVHGFSHVF

Clavanin B79

VFQFLGRIIHHVGNFVHGFSHVF

Clavanin C79

VFHLLGKIIHHVGNFVÝGFSHVF a

Clavanin D79

AFKLLGRIIHHVGNFVÝGFSHVF a

Clavanin E80

LFKLLGKIIHHVGNFVHGFSHVF

Clavaspirin81

FLRFIGSVIHGIGHLVHHIGVAL

a Ý represents a post translationally modified tyrosine residue
As a result of the lack of general attention for the other members of the clavanin family,
clavanin A is the only member for which anything is known beyond relative antibacterial
activity. Clavanin A was discovered to be membrane active, with two distinctly different
activities depending on the pH of the peptide.86, 87 This pH dependence is not surprising given the
relatively high quantity of histidine residues found in its sequence (Table 1-1). Beyond just
histidine, the membrane based activity of clavanin A was found to also rely on its abundant
glycine and phenylalanine residues.82, 88 Clavanin A has been found in both the phagosomes of
macrophage-like hemocytes and the granules of neutrophil-like hemocytes, indicating that the
HDP is utilized both intracellularly and extracellularly.89
As a result of these preliminary studies, the potential for the use of clavanin A as a novel
antibiotic has been well explored. It has been studied in vitro in murine wound infection models,
wherein clavanin A treated S. aureus wounds showed improved healing and eradication of
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bacteria from the wound.90 Additionally, in systemic infection models, clavanin A treatment
resulted in increased survival for both E. coli and S. aureus infected mice. Clavanin A has also
proven effective against biofilms, preventing the formation of E. coli and S. aureus biofilms and
perturbing preformed K. pneumoniae biofilms.91 In addition to the study of unmodified clavanin
A as a potential therapeutic, it has also been conjugated to the surface of iron oxide nanoparticles
and coated onto central venous catheters.84 Clavanin A-Fe3O4 coated catheters were capable of
reducing adhesion of both gram positive (~50%) and gram negative (70-90%) bacteria and
modestly reducing the amount of planktonic bacteria as well, with up to 20% reduction. While
more study of clavanin A is certainly necessary, it appears to be an excellent framework for the
development of novel, peptide-based antimicrobials in the future.
1.6 – Dissertation overview
This dissertation explores the metal binding characteristics of clavanin A with the aim of
elucidating the biological activity of this HDP, so that it can be utilized as a framework for
peptidic antibiotics. Chapter two presents the hypothesis that clavanin A is binding to Zn2+ and
first reports the possibility of nucleolytic activity. Chapter three further explores clavaninA-Zn2+
as a nuclease, presenting a novel mechanism of action for zinc binding AMPs. In chapter four,
bacterial cytological profiling is applied to the study of AMPs for the first time with the aim of
exploring the apparent disconnect between the literature reporting clavanin A as a membrane
active peptide, and our results which indicate a zinc-based DNA cleavage mechanism of action.
Finally, chapter five presents some of the questions generated as a result of the answers obtained
throughout this work, as well as some future directions for the study of not only clavanin A, but
the entire clavanin family.
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The sum of this work provides novel information related to the future development of
antimicrobial interventions. Research resulting in the development of drugs that are less likely to
develop resistance will allow for longer lasting, more effective antimicrobial activity.
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Chapter 2 – Zn2+ Binding Enhances the Antimicrobial Activity of the Tunicate
Peptide Clavanin A

Adapted from: Juliano, S. A.; Pierce, S.; deMayo, J. A.; Balunas, M. J.; Angeles-Boza, A. M., Exploration
of the Innate Immune System of Styela clava: Zn2+ Binding Enhances the Antimicrobial Activity of the
Tunicate Peptide Clavanin A. Biochemistry 2017, 56 (10), 1403-1414.

2.1 – Introduction
The importance of zinc in immunity is well known; however, despite the considerable
advances of recent years, many fundamental aspects of the immunomodulatory and antimicrobial
properties of zinc at the cellular and molecular levels have remained unanswered.1-2 Zinc occurs
as the divalent cation Zn2+ and together with iron and copper is one of the most abundant
transition metals in humans.3 Zinc plays a multitude of roles within human immunology but, not
surprisingly, the complexity of the human immune system has not allowed researchers to fully
unravel all of the biochemical roles of zinc.4-6 Since the complex role of zinc ions in the human
immune system probably evolved from the innate immune system of ancestors in the taxonomic
scale, understanding the role of zinc in the immune response of these ancestors could provide
explanations to its role in humans. Tunicates, like humans, are members of the phylum chordata,
which primarily includes vertebrates, and have the capacity for cell mediated immunity and
humoral immunity.7-9 Importantly, tunicates have been used as primitive models for
understanding fundamental immunological mechanisms by analyzing their processes either in
vivo or in vitro.10-11 Thus, it can be hypothesized that by tracing the evolutionary history of zinc
interactions at the molecular level it should be possible to elucidate mechanisms of zinc
contributions to the immunological response in the complex human immune system.
Key participants in the immune response are also the molecules known as antimicrobial
peptides (AMPs) which can be expressed constitutively or induced by the presence of
pathogens.12-13 AMPs are evolutionarily ancient weapons and are found in all complex living
organisms. In addition to their ability to directly kill microorganisms, AMPs exert
immunomodulatory activities – which has led researchers in recent years to refer to AMPs by the
more general term host defense peptides (HDPs).14-15 The chemical characteristics of AMPs (i.e.
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generally cationic and the presence of about 50% hydrophobic amino acids) allow them to
strongly interact with cellular membranes, particularly those of bacteria. Therefore, many AMPs
were suggested to kill bacteria through fatal interaction with the components of the bacterial
membrane.16-21 More recently, internalization of AMPs with the concomitant damage of an
intracellular target has been uncovered for some peptides.22-25
Our group has been particularly interested in the effect of the binding of metal ions on the
activity of AMPs.26-27 Because zinc and copper ions co-localize with antimicrobial peptides
during immune responses,28-35 we have hypothesized that AMPs with metal-binding motifs can
form either transient or stable complexes with these metal ions to improve their antimicrobial
activity. Herein, we investigate the effect of zinc ions on the activity of an AMP isolated from
the tunicate Styela clava. These investigations are strongly motivated by the search for molecular
models to characterize fundamental immunological roles of zinc.
S. clava, a solitary tunicate, has been shown to express several AMPs that are important
components of its innate immune system.36-39 Extracts from S. clava hemocytes have produced
two families of AMPs, styelins and clavanins.40-42 Immunolocalization studies found clavanins in
the cytoplasm of macrophages and in eosinophilic granulocytes.39 In vitro assays have shown
that one member of the clavanin family, clavanin A (ClavA,
VFQFLGKIIHHVGNFVHGFSHVF-NH2), is active against a broad spectrum of pathogens,
including methicillin-resistant Staphylococcus aureus, and its activity is greater at pH 5.5 than at
pH 7.4.36 The activity at low pH is biologically relevant since the vacuoles of phagocytic
hemocytes from S. clava are likely to have a pH as low as 5 as found in the tunicate Ascidia
ceratodes.43 Such conditions should support optimal antimicrobial activity. Unlike most AMPs,
ClavA remains active at elevated NaCl concentrations (up to 0.3 M).36 In addition, ClavA
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displays a negligible toxicity towards mammalian cells. Because of these properties, ClavA has
been tested in vitro in wound and sepsis murine models and was shown to have potent activity in
both models.44
Due to its similarity to the magainins in size, primary sequence, and antimicrobial
activity, ClavA is thought to act by permeabilizing bacterial membranes.16, 45-46 In the α-helical
conformation, ClavA places His17 and His21 on one face of the helix creating a putative Zn2+
binding site (henceforth referred to as the HX3H motif).47 The i, i + 4 spacing between two
amino acids within an α-helix have been previously exploited to design synthetic metal-binding
motifs.47-49 Specifically, two histidines in positions 7 and 11 in a 16-residue peptide were used to
create a synthetic zinc-based nuclease.47 Coincidentally, hemocytes of aquatic invertebrates
contain large amounts of metal ions, particularly Zn2+, at concentrations higher than in the
surrounding plasma.50-52 For example, in Ostrea edulis, specialized mechanisms allow for
hemocyte uptake of Zn2+ ions up to a 1.2 M concentration.53 Taken together, the presence of a
potential Zn2+ binding site and the large concentrations of this metal ion in marine invertebrate
hemocytes begs the question whether a relationship exists between metal binding and
antimicrobial ability in the activities of ClavA.
In this work, we examine the antimicrobial activity of ClavA in the presence of Zn2+ ions.
We determined that the target of this peptide-Zn2+ complex is located within the cytoplasm, in
addition to the previously reported membrane activity. Our data supports a model where ClavAZn2+ uses its nucleolytic properties to kill bacteria.
2.2 – Results
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The antimicrobial activity of ClavA is potentiated by the addition of Zn2+. In order to
examine whether Zn2+ ions affect the activity of ClavA, we determined its MIC against
Escherichia coli in the presence of Zn2+ and various biologically relevant metal ions using the
broth microdilution method.54 Magainin 2 (GIGKFLHSAKKFGKAFVGEIMNS-NH2) and
Clavanin C (ClavC, VFHLLGKIIHHVGNFVYGFSHVF-NH2) were used for comparison as
well as positive controls. Table 2-1 summarizes the MIC values for ClavA and ClavA incubated
with the various biologically relevant metals. The activity of ClavA is maintained upon addition
of Fe2+ and Ni2+ ions, abolished with Ca2+, and improved after adding Cu2+ and Zn2+ ions. As we
hypothesized, ClavA in the presence of Zn2+ showed the greatest increase in activity, with a 16fold increase, effectively making ClavA-Zn2+ as active as ClavC, the most potent peptide in the
clavanin family.55 ClavC, on the other hand, was found to remain unaffected by the addition of
any of the metal ions reported in this study.
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Table 2-1
Minimum inhibitory concentrations for ClavA with various metal ions

a

Treatment

MIC

ClavA

64 μM

ClavA + Ca2+

>128 μM

ClavA + Fe2+

64 μM

ClavA + Ni2+

64 μM

ClavA + Cu2+

32 μM

ClavA + Zn2+

4 μM

a All metal ion concentrations are 2X that of the peptide. The MICs of the
metals used have all been found to be >256 μM, the highest concentration employed
in this study.

We hypothesized that the increase in activity for ClavA when combined with Zn2+ ions
was the result of the presence of His17 and His21 in its sequence (representing the proposed
HX3H motif). To explore this, mutants of ClavA were synthesized containing substitutions to
one or both of these potentially important histidines. The H17A mutant, ClavA-H17A, and the
double mutant, ClavA-H17A-H21A, had lower activity in the absence of additional Zn2+ ions,
whereas ClavA-H21A remained as active as the wild type. Depending on the position of
histidine to alanine substitutions, an increase of the helical content of peptides can be observed,56
which in turn can result in an increase of antimicrobial activity.27 Circular dichroism shows that
the three His to Ala mutants have a larger percentage of helicity as compared to ClavA (Figure
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2-1), but ClavA-H21A has the lowest increase in helicity. Because ClavA-H17A and ClavAH17A-H21A are less active than ClavA-H21A, helicity increase is not the reason for the better
antimicrobial activity in ClavA-H21A as compared to the other two mutants. Notably, marked
differences were observed when the peptides were combined with zinc ions. Table 2-2
summarizes these results as well as the activities of the other peptides used in this study in the
presence and absence of Zn2+. ClavA-H17A and ClavA-H17A-H21A remained inactive, whereas
ClavA-H21A showed a modest two-fold increase in activity in the presence of additional Zn2+.
These results suggest that His17 is more important for the formation of a putative ClavA-Zn2+
complex (this is not necessarily a 1:1 complex as the nomenclature might suggest; however, we
prefer to use this notation until we learn more about the nature of this complex).
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Figure 2-1
Circular Dichroism spectra of ClavA, ClavA-H17A, ClavA-H21A and ClavA-H17AH21A in 50% 2,2,2-trifluoroethanol 50% MES 5.5 to show the increased helicity of the
alanine substituted mutants. The increase in α-helicity can be observed as a decrease in
the minima at 208 nm and 222 nm.

We also determined MBC values. ClavA had an MBC equal to its MIC, which means
that the growth inhibition seen at that concentration was due to the peptide bringing about cell
death. In the presence of Zn2+, however, the MBC was 8 μM, twice the MIC, meaning that at
MIC concentrations of ClavA-Zn2+ there were still living E. coli cells that were in some way
inhibited from growing by the peptide. The 8-fold decrease in MBC between ClavA and ClavA-
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Zn2+ indicates an improvement in the overall bactericidal activity of ClavA upon addition of Zn2+
ions.
Table 2-2
Minimum inhibitory concentrations for ClavA, ClavA Mutants, ClavC and Magainin
2 without and with Zn2+ a
Treatment

MIC without Zn2+

MIC with Zn2+

ClavA

64 μM

4 μM

ClavA-H17A

>128 μM

>128 μM

ClavA-H21A

64 μM

32 μM

ClavA-H17A-H21A

>128 μM

>128 μM

ClavC

4 μM

4 μM

Magainin 2

8 μM

8 μM

a Zinc ion concentrations are 2X that of the peptide. The MIC of Zn2+ has been found to be
>256 μM, the highest concentration employed in this study.
ClavA shows improved activity even at sub-stoichiometric Zn2+ concentrations. In
order to look at how the concentration of Zn2+ affects the activity of ClavA, we incubated
bacteria with 8 μM ClavA and varied the concentration of Zn2+ present. Figure 2-2 summarizes
these results. Percent viability was determined by plating dilutions of each sample, counting
colonies, and comparing to an untreated control. All of the concentrations of Zn2+ used in the
study, from 16 μM to 2 μM, resulted in clearance of a vast majority of the E. coli, and growth
was only present in samples which contained no additional Zn2+ because the concentration of
ClavA used was below the MBC for the peptide alone. These results indicate that even at very
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low levels of Zn2+, ClavA activity is greatly improved. This could indicate that one Zn2+ ion
interacts with several ClavA units, though more study is required for definitive proof of this.

Figure 2-2
Effect of varied Zn2+ concentration on the antimicrobial activity of 8μM ClavA. These data are
plotted with a logarithmic scale on the y-axis. Values represent the average of three trials ±
standard error from mean (*, P≤0.05; N.S. =not significant).

Styela clava hemolymph contains a sufficient concentration of Zn2+ for biological
relevance. We next evaluated whether the Zn2+ concentration that was observed to increase the
activity of ClavA in the antimicrobial assays was biologically relevant. For this purpose, we
harvested live S. clava and determined the concentration of Zn2+ ions in the hemolymph, a fluid
found in invertebrates which serves as a blood analogue, using atomic absorption spectroscopy.
The concentration of Zn2+ ions was determined to be 26.7 ± 7.1 μM, indicating that enough Zn2+
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ions are found in the hemolymph to potentiate the activity of ClavA. Some percentage of these
ions are likely to be tightly bound to proteins in the hemolymph or hemocytes; however,
considering the fact that the viability of E. coli was <1% at c.a. 10% of the total measured
tunicate Zn2+ concentration (Figure 2-2), it is likely that the labile pool of zinc ions is large
enough to potentiate ClavA in vivo. As in many aquatic invertebrates, S. clava hemocytes likely
contain greater concentrations of Zn2+ ions than the surrounding sea water due to the presence of
special mechanisms that accumulate Zn2+.53
Circular dichroism shows that Zn2+ binding results in a conformational change in
ClavA. To determine whether ClavA is binding the Zn2+ or not, circular dichroism (CD) was
performed on a series of titrations of a 50 μM solution of ClavA with Zn2+ in MES 5.5. As can
be seen in Figure 2-3, there is a distinct concentration dependent change in the CD spectra upon
the addition of Zn2+. Overall, it appears that the percent α-helix increases with increasing Zn2+
concentration. These results, coupled with the observed change in activity upon Zn2+ incubation
seem to indicate that Zn2+ binding is occurring and some sort of ClavA-Zn2+ complex is being
formed.
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Figure 2-3
CD spectrum of 50 μM ClavA titrated with Zn2+ in MES buffer (pH = 5.5). The changes
observed upon the addition of Zn2+ seem to indicate that binding of the ion is occurring. The
helicity increases from 4.2 % for ClavA alone to 9.6 % in the presence of 250 μM Zn2+.

ClavA exerts its bactericidal activity faster in the presence of Zn2+. We next sought to
determine the rate at which ClavA and ClavA-Zn2+ killed bacteria. To do this, we performed a
time-kill kinetics study by counting viable colonies from a bacterial suspension in a solution of
ClavA or ClavA-Zn2+. Figure 2-4 shows that when both ClavA and ClavA-Zn2+ are at 64 μM,
ClavA-Zn2+ (red) causes total clearance of the E. coli after about 2 hr, whereas apo-ClavA (blue)
does not completely clear out the culture at four hours of treatment. These data imply that the
killing mechanism of ClavA in the presence of Zn2+ is faster than that of the peptide alone.
ClavA with Zn2+ at its MBC appears to be bactericidal at a lower rate than ClavA alone;
however, it does so at 12.5% of the concentration of ClavA. ClavA-Zn2+ at the MIC value
appears to only slightly inhibit the growth of E. coli over buffer alone. Although a horizontal or
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downward curve is expected for a ClavA-Zn2+ at its MIC, upward trending curves have been
observed for other antimicrobial agents at their MIC values.57-58 It is also plausible that the
upward curve for ClavA-Zn2+ at its MIC is due to matrix effects coming from the media. LB
media contains tryptone, which is a partial digest of casein by the protease trypsin. This digest
leaves behind oligopeptides from casein, which are known to bind to Zn2+,59 and could deprive
ClavA of zinc ions, reducing its overall efficacy.

Figure 2-4
Time kill kinetics data for ClavA, ClavA-Zn2+, and Magainin 2. [ClavA] = 64 μM, the MIC
and MBC values for the peptide. MIC and MBC values for ClavA-Zn2+ are 4 μM and 8 μM,
respectively. Magainin 2 was used at its MIC, 8 μM. MES 5.5 represents an untreated control.
Each point represents mean ± standard error from mean. In some cases, error bars are too small
to be visible.
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ClavA-Zn2+ causes membrane depolarization faster and at a lower concentration
than ClavA. ClavA has been shown to cause depolarization of the lipid membrane of bacteria.46,
60

In light of this, we next sought to determine the effects of Zn2+ ions on the membrane

depolarization activity of ClavA through the use of the membrane potential sensitive probe,
DiSC3(5). When a cell is undamaged, DiSC3(5) is drawn to the membrane and its fluorescence is
self-quenched. If the peptide attack depolarizes the cell membrane, the dye is no longer drawn to
the membrane and dissociates, causing DiSC3(5) to fluoresce. The amount of fluorescence
recovered after treatment is proportional to the amount of membrane depolarization. B. subtilis
was used for these experiments because Gram-positive bacteria do not require special
pretreatment, whereas Gram-negative bacteria require pretreatment with EDTA which would
have chelated the Zn2+. A 50% solution of the nonionic surfactant T-X100 was used as a positive
control, causing complete depolarization of the bacterial membrane, resulting in a 12 to 15–fold
increase in fluorescence.
We first looked at the kinetics of membrane depolarization (Figure 2-5A) and found that
ClavA-Zn2+ achieves maximum depolarization faster than ClavA alone. Despite the initial rate of
depolarization being higher for ClavA-Zn2+ than for the peptide alone, both reach the same
amount of depolarization after one hour. We also wanted to explore the concentration
dependence of depolarization and potentially see if ClavA-Zn2+ was causing depolarization at a
lower concentration. As can be seen in figure 2-5B, ClavA-Zn2+ reaches maximum
depolarization between 8 and 16 μM whereas it takes 64 μM ClavA to reach the same level. This
result is consistent with MIC and MBC measurements for the ClavA and ClavA-Zn2+. It is
possible that the overall improved membrane depolarization activity is due to stronger
interactions with the bacterial membrane as a result of Zn2+ histidine binding as described by
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Kurut and coworkers.61 When these data are taken in conjunction with the result of the time kill
kinetics study, it becomes clear that not only does the addition of Zn2+ improve the activity of
ClavA, it also shortens the time required for ClavA to bring about cell damage.

Figure 2-5
B. subtilis membrane depolarization for ClavA and ClavA-Zn2+. (A) Depolarization as a
function of time. Error bars were removed for clarity. (B) Depolarization as a function of
peptide concentration.

ClavA does not cause pores large enough to allow β-galactosidase leakage. To
determine the cause of the observed membrane depolarization we investigated the formation of
pores. For this experiment, β-galactosidase was overexpressed in E. coli by exposure to IPTG.
Cells were then incubated with either ClavA, ClavA-Zn2+, or T-X100, and β-galactosidase
leakage was measured in the supernatant through cleavage of ONPG, which produces a yellow
product.62 ClavA causes about 35% β-galactosidase leakage and ClavA-Zn2+ causes about 20%
relative to T-X100 (Figure 2-6). This low-level leakage is most likely due to death of the cells,
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rather than pore formation, considering cell killing has been observed to occur within one hour
(Figure 2-4). Large stable pores would be required to cause β-galactosidase leakage, and no
significant leakage is observed. As a result of these data it can be concluded that stable pore
formation is not the cause of the increased depolarization observed with ClavA-Zn2+. However,
this does not entirely eliminate membrane poration as a potential cause for the observed
depolarization. AMPs have been shown to cause membrane damage through the formation of
transient or disordered toroidal pores, which only requires small quantities of peptide, with the
pore walls being formed by lipid head groups.63-64 These transient smaller pores have been
shown to work similarly to ion channels, causing depolarization by abolishing membrane
potential, and their presence can often be detected by an increase in potassium ion concentration
in solution.65
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Figure 2-6
β-galactosidase leakage from E. coli cells as caused by ClavA and ClavA-Zn2+. T-X100 was set
to 100% for each trial. Each value represents mean ± standard error from mean.

Potassium efflux is not the sole cause of membrane depolarization and does not
cause cell death. Previous work performed by van Kan and coworkers provides evidence that
ClavA is capable of causing membrane poration and K+ leakage.46 We aimed to explore the
difference in depolarization rates we observed for ClavA and ClavA-Zn2+ and identify whether it
was a function of some difference in the K+ leakage between the two treatments. As can be seen
in Figure 2-7, both ClavA and ClavA-Zn2+ cause potassium leakage. The fact that the data
presented here differ from those published by van Kan et al. likely originate from differences
between Lactobacillus sake and B. subtilis. ClavA and ClavA-Zn2+ cause K+ leakage at
relatively similar rates despite the fact that the time-dependent depolarization results (Figure 25A) indicate that ClavA-Zn2+ reaches maximum depolarization of the bacterial membrane
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roughly 30 min faster than ClavA without Zn2+. This would seemingly indicate that some other
mechanism of attack is employed by ClavA-Zn2+, causing depolarization separate from the K+
leakage activity. The depolarization and K+ leakage, however, are likely not bringing about cell
death because the time kill kinetics data (Figure 4) show that at one hour there is roughly 70%
survival in the case of ClavA and that ClavA-Zn2+ is bacteriostatic at the concentration used for
K+ leakage and depolarization.

Figure 2-7
Potassium leakage from B. subtilis cells as caused by ClavA and ClavA-Zn2+ at their respective
MICs. Each sample was sonicated to determine 100% potassium content. Each point represents
mean ± standard error from mean.

ClavA has different localization in E. coli cells with and without Zn2+ present. To
help us elucidate the cause of membrane depolarization, we used fluorescence microscopy.
ClavA is proposed to be a membrane active peptide; however, no microscopy studies have been
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done to either prove or disprove these claims. A derivative of ClavA was synthesized with a
5(6)-carboxytetramethylrhodamine (TMR) label on a lysine residue added to the peptide
sequence instead of Phe4 (Figure 2-8), and this derivative (ClavA-TMR) was used for confocal
microscopy studies. ClavA-TMR was first confirmed to be functionally similar to ClavA by
obtaining MIC values for the fluorescent peptide in the presence and absence of Zn2+. As can be
seen in Table 2-3, ClavA-TMR and ClavA-TMR-Zn2+ have MICs which are close to those of the
wild type peptide, and in both cases, the peptides incubated with Zn2+ have 16-fold lower MIC
values. This provides evidence that the addition of the fluorescent label did not significantly alter
the activity of ClavA.
Table 2-3
Minimum inhibitory concentrations for ClavA and ClavA-TMR in the presence
and absence of Zn2+ions a
Treatment

MIC without Zn2+

MIC with Zn2+

ClavA

64 μM

4 μM

ClavA-TMR

32 μM

2 μM

a Zinc ion concentrations are 2X that of the peptide. The MIC of Zn2+ has been
found to be >256 μM, the highest concentration employed in this study.
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Figure 2-8
Schematic representation of the addition of 5(6)-carboxytetramethylrhodamine (TMR) to ClavA.
A mutant sequence of ClavA (VFQFLGKIIHHVGNFVHGFSHVF-NH2) containing a lysine
residue protected by a 4-methyltrityl group (Mtt) instead of Phe4 was used. We hypothesized that
replacing a hydrophobic residue by the amino acid containing the hydrophobic TMR label will
have the lowest impact on the activity of the peptide. Reaction conditions are as follows: (i) LysMtt deprotection with 1% trifluoroacetic acid (TFA) in dichloromethane (DCM); (ii) addition of
TMR to the ε-amino group of Lys was performed using four times excess of TMR, 2-(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate (HBTU), and
diisopropylethylamine (DIEA) dissolved in dimethylformamide (DMF); (iii) cleavage of the
peptide from the resin using a mixture of 95% TFA, 2.5% H2O and 2.5% triisopropylsilane (TIS).
The microscopy experiments were performed at 8 μM peptide to avoid saturation of the
fluorescence emission from TMR. The micrographs of ClavA-TMR attack (Figure 2-9A and 29B) show E. coli with peptide internalized after 1-hour incubation. This observation in
combination with the time kill kinetic results hints at a possible mechanism involving an internal
target for ClavA. This is somewhat contrary to literature findings, which strongly suggest that
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ClavA targets the bacterial membrane.45-46 In addition to internalization, we also observed some
bacterial membrane damage in roughly 10% of the cells observed. For example, in figure 2-9B,
the bacterium in the lower right corner appears to have distortion in the membrane (black
arrows), an indication of damage, most likely from the initial attack of the peptide. These spots
of damage are reminiscent of the blebs caused by human defensin 5, though the resolution of the
microscope is not high enough to make them out for certain, and more powerful techniques
would be needed to confirm the presence of blebs.18 If membrane damage is occurring, this could
explain why previous studies report membrane activity as ClavA damages the membrane on the
way to an internal target, likely DNA. Images of ClavA-TMR-Zn2+ attack (Figure 2-9C and 29D) show that, in roughly 75-80% of the E. coli imaged, the peptide accumulates primarily on
the membrane (Figure 2-9C). We propose that this accumulation is likely due to the formation of
a peptide-Zn2+-lipid interaction and eventually promotes internalization of the ClavA. The
remaining 20-25% of the cells incubated with ClavA-TMR-Zn2+ showed internalization of the
complex (Figure 2-7D), with images appearing similar to what was seen for ClavA-TMR. This
could again point to an internal target for ClavA. ClavA-Zn2+ also has the interesting feature of
creating bright loci on the membranes of about 60% of the cells imaged (Figure 2-9C and 2-9D,
white arrows). Of the cells that contain these bright loci there is only one locus per cell. These
loci appear to be concentrated regions of peptide and not a feature of the bacterial membrane due
to the fact that in spots where a bright locus is found there is no evidence of a damaged
membrane in the DIC. Overall, the microscopy studies, combined with the leakage studies
reported above, indicate that the observed depolarization probably arises from the ClavA-Zn2+lipid interaction, which is likely not the sole cause of the observed cell death.

50

Figure 2-9
Fluorescence micrographs of ClavA-TMR and ClavA-TMR-Zn2+ localizing in E. coli cells. Cells
were all grown to ~1x109 cfu/mL and ClavA concentration is 8 μM. (A) ClavA-TMR showing
internalization. (B) ClavA-TMR showing internalization with membrane damage, potentially
bleb formation (black arrows). (C) ClavA-TMR-Zn2+ showing a membrane bound state with
bright loci potentially representing highly concentrated regions of peptide (white arrows). (D)
ClavA-TMR-Zn2+ showing internalization with a bright locus potentially representing a highly
concentrated region of peptide (white arrow).
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ClavA is less active against E. coli with diminished cytoplasmic Zn2+ concentration.
If ClavA is localizing in the cytoplasm it is important to look at the relevance of cytoplasmic
Zn2+ concentrations on ClavA activity. To that end we tested the activity of ClavA on three E.
coli strains with deletions to the ZnuABC transporter complex genes (Table 2-4). ClavC was
included as a control because Zn2+ concentration has no effect on the activity of the peptide
(Table 2-2). The ΔznuA mutant (JW5831) has a deletion in the zinc binding portion of the
transporter (ZnuA), leaving the pore (ZnuB) and ATPase (ZnuC) portions intact. For both ClavA
and ClavA-Zn2+ the activity decreases, reflected in the MIC increasing to 128 μM (a 2- and 32fold increase respectively), whereas the activity, for ClavC, our control peptide which does not
utilize Zn2+, remains unchanged. For the ΔznuB and ΔznuC strains (JW1848 and JW1847,
respectively) the MIC for ClavA alone increases beyond the scope of the experiment, whereas
the MIC for ClavA-Zn2+ increases 16-fold. For these strains, the activity of ClavC improves
slightly, but this variation could be due to a side effect of the mutation process. The remaining
activity of ClavA in the mutants is most likely due to the fact that some zinc is likely to diffuse
into ZnuB without the aid of ZnuA. Overall it appears that cytoplasmic zinc is important to the
activity of ClavA, especially when the peptide is not pre-exposed to zinc.
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Table 2-4
ClavA, ClavA-Zn2+ and ClavC antimicrobial activity against three mutant E. coli strains
with deleted zinc ion transporters a
Peptide

MIC (JW5831)

MIC (JW1848)

MIC (JW1847)

ClavA

128 μM

>128 μM

>128 μM

ClavA-Zn2+

128 μM

64 μM

64 μM

ClavC

4 μM

2 μM

2 μM

a

JW5831, JW1848 and JW1847 are deletion mutants of znuA, znuB and znuC respectively.

Each column represents the MIC against each mutant bacteria strain.
In order to prove that the change in activity is due to the decreased internal Zn2+
concentration from the deletion of the zinc transport system, and not just some feature of the
deletion of a membrane protein, we measured the activity of ClavA, ClavA-Zn2+ and ClavC
against three E. coli strains with deletions to the nickel transport system, NikABC (Table 2-5).
Overall, although the MIC values are not the same, as expected for different E. coli strains, the
pattern observed for the wild type remains (i.e. ClavA shows improved activity in the presence
of additional Zn2+ ions). These results confirm that the deletion of Zn2+ transporters, and the
subsequent decrease in intracellular Zn2+ concentration is what causes the increase in MIC
observed above.
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Table 2-5
ClavA, ClavA-Zn2+ and ClavC antimicrobial activity against three mutant E. coli strains
with deleted nickel ion transporters a
Peptide

MIC (JW3441)

MIC (JW3442)

MIC (JW3444)

ClavA

32 μM

32 μM

32 μM

ClavA-Zn2+

8 μM

8 μM

8 μM

ClavC

4 μM

2 μM

2 μM

a

JW3441, JW3442 and JW3444 are deletion mutants of nikA, nikB and nikD respectively.

Each column represents the MIC against each mutant bacteria strain.
ClavA-Zn2+ cleaves supercoiled DNA in vitro. Because cytoplasmic zinc appears to be
important to the function of ClavA and the microscopy shows ClavA present in the cytoplasm, it
is likely that ClavA-Zn2+ is forming in the cytoplasm and damaging an internal target. While
most AMPs are active against bacterial membranes, a small subset have been shown to be
internalized and bind to DNA.66-69 Therefore, ClavA-Zn2+ was tested for its in vitro DNA
cleavage ability. As shown in figure 2-10A, DNA cleavage by ClavA pre-incubated with Zn2+
ions can be visibly observed after 60 min at room temperature, with the supercoiled and nicked
forms decreasing in intensity, along with a concomitant increase in the linearized form. In
addition, the linearized band can be observed to form a smear, indicating that not only is the
DNA linearized, it is also being further cleaved into smaller pieces. A steady decrease in
supercoiled DNA was observed across all of the time points (Figure 2-10B). The nicked form
can be observed to increase at first, but after 30 min it starts to decrease, while at the same time
the amount of linearized DNA increased.
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Figure 2-10
In vitro DNA cleavage gels representing pUC19 DNA treated with (A) 1 μM ClavA-Zn2+
quantified in (B), (C) 1 μM ClavA and 20 μM DTPA quantified in (D), (E) 2 μM Zn2+
quantified in (F), (G) pUC19 alone quantified in (H), (I) 1 μM ClavA-H17A-Zn2+ quantified
in (J), and (K) 1 μM ClavA-H21A-Zn2+ quantified in (L). S = supercoiled DNA, N = nicked
DNA and L = linear DNA.

To prove that ClavA and Zn2+ together are required for DNA cleavage to occur, several
controls were run. Figures 2-10C and 2-10D show that, when exposed to ClavA in the absence of
Zn2+, the relative concentrations of each of the forms of DNA remained constant. The chelator
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DTPA is necessary for this system since Zn2+ has a ubiquitous presence in laboratory settings.70
This same unchanging phenotype can also be observed for Zn2+ and DNA (Figures 2-10E and 210F), as well as DNA in the absence of treatment (Figures 2-10G and 2-10H). The level of DNA
damage was also found to be dependent on the concentration of ClavA-Zn2+ present in the
sample with lower ClavA-Zn2+ concentrations resulting in lower relative nuclease activity (not
shown). These results imply that DNA damage could be a part of the mechanism of ClavA,
specifically when bound to Zn2+.
In order to further investigate our proposed Zn2+ binding site, we tested for DNA
cleavage using our H17A and H21A mutants incubated with Zn2+. As hypothesized, no DNA
damage is observable for either of these molecules (Figure 2-8I – Figure 2-8L). These results
provide further evidence for the importance of these residues, and the DNA binding ability of the
HX3H motif.
2.3 – Discussion
In these studies, ClavA has been shown to have increased antimicrobial activity in the
presence of Zn2+ not only through a 16-fold reduction in MIC, but also through increased rate of
cell killing. The work presented above provides insight not only into the activity of ClavA in the
presence of Zn2+ ions, but also sheds light on how ClavA interacts with bacteria. The results of
the membrane depolarization, β-galactosidase leakage and potassium leakage experiments
combine to paint a picture of a peptide that is membrane active and forms small pores. This
behavior has been previously described by van Kan and co-workers, who established the
important role played by phenylalanine and glycine residues in the interaction of ClavA with the
bacterial membrane.46, 60 The question that arises from our results is how Zn2+ ions potentiate the
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activity of ClavA. It is conceivable that similarly to DCD-1L, a peptide that oligomerizes into a
trimer of dimers,71-72 ClavA uses Zn2+ ions to self-assemble into a higher oligomeric state to
destabilize the bacterial membrane. Our ESI-MS data indicates the presence of a ClavA2-Zn2+ (a
dimer of ClavA bound through a Zn2+ ion) in the gas phase; however, such a complex might not
exist in solution. On the other hand, higher oligomers, ClavAx-Zn2+, could also exist in solution,
but were not detected under the ionization conditions used in the ESI-MS experiment.
Interestingly, zinc binding to His17 and His21 can result in a nucleation site for α–helix folding
once the peptide interacts with the membrane,73 since the CD measurements determined in buffer
indicated that upon Zn2+ binding the α–helicity of ClavA increases from 4.2% to 9.6%.
Alternatively, the interaction of Zn2+ with the phospholipid membrane is known to result in less
hydrophilic phosphate groups,74 which could favor the binding and internalization of ClavA
without the need for an oligomer to form. Both scenarios need to be tested before any
conclusions can be reached.
It is clearer that a large component of the synergy between ClavA and zinc ions occurs in
the cytoplasmic space. As evidenced by the microscopy images, ClavA and/or a ClavA-Zn2+
complex is internalized before cell killing occurs. Furthermore, E. coli mutants with deleted zinc
transporters are less susceptible to the antimicrobial activity of ClavA. It is unlikely that a
putative ClavA-Zn2+ complex will use the ABC transporter designed for Zn2+ given the large
difference in size between the metal ion and any ClavA-Zn2+ complex. Within the cytoplasmic
space, the ClavA-Zn2+ complex can target different biomolecules. Herein, we propose that
similarly to other antimicrobial peptides, the ClavA-Zn2+ complex targets DNA.22, 26, 68, 75-77 The
proposed nuclease activity of ClavA in combination with Zn2+ ions is a novel mechanism for
natural AMPs that bind zinc. Histatin 5, a human salivary peptide binds to copper and zinc ions
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and has nuclease activity;78-79 however, when the copper binding site is removed, the DNA
cleavage activity is abolished despite the presence of Zn2+.79 Other host defense peptides/proteins
that interact with Zn2+ ions have been previously reported; however, no DNA cleavage activity
has been observed in those cases. For example, the human protein S100A12, a protein expressed
and released by neutrophils,80 acts by binding and sequestering Zn2+ ions depriving bacteria from
such an essential metal ion.81 The aforementioned DCD-1L, a peptide derived from dermcidin,
adopts an α-helix conformation in which the binding of the Zn2+ ions occurs via residues in an i, i
+ 4 configuration, but no DNA cleavage activity has been reported.71 Kappacin, an AMP
produced from κ–casein found in bovine milk, enhances its membranolytic effect in the presence
of Zn2+ ions.82 Similarly, an antibacterial hexapeptide isolated from human amniotic fluid
containing one lysine, two glycine and three glutamic acid residues potentiates its activity by
Zn2+ via an unknown mechanism.83 Interestingly, the presence of Cu2+ and Mg2+ cations were do
not have the same effect.83 Brogden et al. have also reported that ovine pulmonary surfactantassociated anionic AMPs require zinc as a cofactor.84 However, not all anionic AMPs increase
their activity in the presence of zinc ions. For instance, maximin H5, an anionic AMP isolated
from the toad Bombina maxima, does not increase its activity in the presence of up to 1 mM zinc
ions. Finally, we can also add to this collection of examples mutants of the Cardin and Weintraub
motif peptides containing histidine residues instead of the amino acids Lys and Arg. These
peptides become more active in the presence of Zn2+ ions; however, no cytoplasmic activity have
been reported. For the mutants of the Cardin and Weintraub motif peptides, it was hypothesized
that the metal ion increases the affinity of the peptides towards heparin.85
Overall, we hypothesize that the already recognized membrane activity of ClavA
combines with its nuclease activity to create a putative “one-two-punch” of antimicrobial
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activity. Additional studies will be necessary to elucidate the structure of the ClavA complex
with Zn2+. A better understanding of the role of Zn2+ ions in the chemistry of ClavA and other
tunicate AMPs is key to obtain a better understanding of zinc trafficking and its role in the
immune system of tunicates. In addition, the unique strategy reported here for ClavA will be
useful for the development of novel AMP-based strategies for the treatment of infections. This is
particularly important since ClavA is being targeted for the development of new peptide-based
antimicrobial strategies since the peptide and its nanoformulations have been shown to be
effective for the clearing of sepsis infections in mice.86-87
2.4 – Methods
Solid Phase Peptide Synthesis, Purification and Identification. ClavA and all
substitution and fluorescent mutants were synthesized purified and quantified using methods
previously described by our lab.26 Briefly, peptides were synthesized manually via standard
solid-phase peptide synthesis using fluorenylmethyloxycarbonyl (Fmoc) chemistry on Rink
amide resin (Matrix Innovation, Quebec, Canada).
Peptides used for fluorescence microscopy were labeled with 5(6)carboxytetramethylrhodamine (TMR; Sigma) on a modified lysine residue. The phenylalanine in
the fourth position of the peptide sequence was replaced with a lysine protected with a 4methyltrityl group, which can be selectively deprotected at low acid concentrations. The lysine
amide group was then used to attach to the carboxylic acid of the TMR. A scheme of this
synthesis can be found in Figure S1.
Peptides were then purified via reverse phase-HPLC (Shimadzu LC-20AD, USA) using a
C18 semi-prep column (Grace Davidson, Deerfield, IL, USA) and masses were confirmed via
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electrospray ionization mass spectrometry in positive ion mode. Purity was determined using
reverse phase-HPLC with a C18 analytical column (Thermo). Fractions containing the purified
peptide were lyophilized overnight and dissolved in nanopure water. The peptides were then
quantified via UV-Vis spectrophotometry using molar extinction coefficients for the amino acid
residues and the peptide bond as determined by Kuipers and Gruppen.88 All peptides were stored
at 4°C in solution and diluted before each experiment.
Antimicrobial Assay. Antimicrobial activity was determined using the broth
microdilution method described by Hancock.54 Three to five colonies of Escherichia coli
(MG1655) or Bacillus subtilis (PS832) were added to Luria-Bertani broth (LB; Amresco, Solon,
OH, USA) containing 2-(N-morpholino) ethanesulfonic acid buffer (MES; Sigma-Aldrich)
adjusted to pH 5.5 (LB 5.5), and incubated until mid-logarithmic phase was achieved,
OD600=0.4-0.6 (3-4 hours for E. coli, 4-6 hours for B. subtilis). Bacteria cultures containing 1 x
106 cfu/mL were then prepared in fresh media for MIC determination. A pH of 5.5 was chosen
for these experiments because much of the previous research on ClavA shows that its activity is
optimal at lower pH values.36, 45-46 Additionally, this pH has been found to be biologically
relevant for phagocytic hemocytes. For example, the pH of hemocytes isolated from the tunicate
Ascidia ceratodes were found to be as low as 5.43
Peptide stock solutions were prepared at 2x the maximum experimental concentration in
50 mM MES pH 5.5 (MES 5.5), and 50μL of two-fold serial dilutions were made in a 96-well
polypropylene plate (Greiner). To the serial dilutions were added 50μL of a bacterial suspension
of 1 x 106 cfu/mL, for a final bacteria concentration of 5 x 105 cfu/mL. Plates were then
incubated at 37°C for 18-20 hr and the minimum inhibitory concentration (MIC) was observed
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as the lowest concentration that visually inhibited bacterial growth. The MIC values reported
represent the mode of three trials.
For experiments using metal ions, the 2x peptide dilutions were incubated with solutions
containing the metal ions used in the experiments at 2x peptide concentration for about thirty
minutes prior to the addition of the bacteria suspension to allow adequate time for binding. The
peptide-metal solutions were then used in the same manner stated above. All of the metal ions
used showed MICs greater than 256 μM, the maximum metal concentration used in any
experiment.
Minimum bactericidal concentration (MBC) was determined after performing the
antimicrobial assay by spotting 10 μL of the MIC mixture and the next two higher peptide
concentrations onto an agar plate, and incubating overnight. The MBC values reported are the
peptide concentrations that resulted in agar plates without bacterial growth.
Varied Zn2+ Concentration Assay. To determine the optimal Zn2+ concentration for
running experiments as well as how much Zn2+ is required to potentiate the activity of ClavA,
one concentration of ClavA was incubated with several different concentrations of Zn2+ and
bacterial growth was monitored. E. coli cultures of 1x106 cfu/mL were prepared using the same
procedure as for the antimicrobial assay. These cultures were incubated with solutions containing
ClavA at a final concentration of 8 μM and either 0 μM, 2 μM, 4 μM, 8 μM, or 16 μM Zn2+. The
mixtures were then incubated at 37°C for 4 hr, after which dilutions were plated on LB agar and
allowed to grow overnight at 37°C. The next morning colonies were counted and percentages
were calculated based on a control culture containing neither ClavA nor Zn2+ as 100%.
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Tunicate Collection and Hemolymph Harvest. In order to determine biologically
relevant Zn2+ concentrations, S. clava tunicate specimens were collected from shallow water
dock lines at Avery Point, CT, in January of 2016 (41° 18.975 N, 72° 3.647 W). Tunicates were
rinsed in sterile DI water and stored in 10% menthol (w/v) before dissection back at the lab.
The hemolymph was harvested from the tunicates via dissection and heart puncture. The
hemolymph was then filtered through a 70 micron mesh nylon filter (Carolina Biological Supply,
Burlington, NC, USA) and stored at -20°C until ready to use.
Atomic Absorption Spectroscopy. Zn2+ concentration was measured using atomic
absorption spectroscopy (AAS). Digestion of the samples was required prior to AAS analysis.
Hemolymph samples were first dried via heating at 120°C in an aluminum block heater for about
2 days in glass test tubes with Teflon screw caps removed. Next, 5 mL of 70% nitric acid
(Sigma-Aldrich) was added to each tube and allowed to rest at room temperature for one hour.
Tubes were then capped and heated in an aluminum heating block for 3 hr at 90°C. Samples
were then cooled to room temperature, diluted to 50 mL and analyzed by AAS along with
standards prepared in a similar process.
Circular Dichroism Spectroscopy. CD spectra both for the purpose of determining αhelical content of ClavA and its mutants, as well as for determining the effect of Zn2+ on ClavA
were obtained using a Jasco J-710 spectropolarimeter. All samples contained 50 μM ClavA. The
experiments performed on ClavA and the mutants were performed in a 50:50 solution of H2O
and 2,2,2-trifluoroethanol (TFA). The Zn2+ titration experiments were performed in MES 5.5
buffer. The molar ellipticity,𝛩, was calculated from the raw data using the following equation:

𝛩=𝜃×

𝑀𝑅𝑊
𝑙∗𝑐
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where θ is the measured ellipticity, 𝑀𝑅𝑊 is the mean residue molecular weight of the peptide,
calculated as the molar mass divided by the number of peptide bonds, 𝑙 is the pathlength in cm,
and 𝑐 is the concentration of the peptide in mg/mL.89 The percent α-helix reported was calculated
using the equation:

%𝛼 ℎ𝑒𝑙𝑖𝑥 = −100 ×

𝛩222 − 3000
33000

where 𝛩222 is the molar ellipticity at 222 nm.90
Time Kill Kinetics. E. coli cultures of 1 x 106 cfu/mL were prepared using the same
procedure as was used for the antimicrobial assay. Aliquots of the diluted culture were then
mixed with the indicated treatments in equal volumes, then incubated at 37°C for the indicated
time points. At each time point, aliquots of 10 μL were removed, serially diluted to 1:1000, and
plated on LB agar and grown for 16-18hr. Colonies were counted and plotted against time. In
instances where it was necessary to do so, dilutions were adjusted up or down to obtain plates
with an appropriate number of colonies. Cultures were considered cleared when 100 μL of
culture plated directly produced no colonies, indicating fewer than 10 cfu/mL.
DiSC3 (5) Depolarization Assay. B. subtilis cultures were grown at 37°C in LB 5.5 to
mid-logarithmic phase, OD600=0.4-0.6, washed three times with MES 5.5 and diluted to OD600=0.01 in MES 5.5 containing 20mM glucose (Fisher). The bacteria were then incubated for one
hour with 0.4μM 3,3'-dipropylthiadicarbocyanine Iodide (DiSC3(5); Chemodex, St. Gallen,
Switzerland), a membrane-potential active fluorophore. The one hour incubation allows time for
the fluorophore to be drawn to polarized membranes and self-quench, as evidenced by the >90%
decrease in fluorescence. The bacteria solutions were then mixed with serial dilutions of peptide
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treatments, 50% Triton X-100 (T-X100; Fisher), or MES 5.5. T-X100 was used as a positive
depolarization control, and MES 5.5 was the negative control. Fluorescence was monitored every
2 min for 1 hr at an excitation wavelength of 622 nm and an emission wavelength of 670 nm.
Values represent the percent fluorescence recovery averaged over three trials ± standard error.
β-Galactosidase Leakage Assay. The amount of β-galactosidase leakage caused by
ClavA or ClavA-Zn2+ was determined as described previously.26, 91-92 E. coli transformed with a
gene for cytoplasmic β-galactosidase production were grown in LB 5.5 at 37°C to OD600=0.40.6, after which overexpression of β-galactosidase was induced for 1 hr with the addition of 1
mM final concentration of isopropyl β-D-1-thiogalactopyranoside (IPTG; Fisher). Cells were
then washed three times in MES buffer and suspended in fresh LB 5.5. Aliquots of the culture
were then mixed with either ClavA, ClavA-Zn2+, or 50% T-X100. Mixtures were incubated for 1
hr at 37°C, then centrifuged at 4400rpm and 4°C for 10 min and the supernatant, containing any
leaked β-galactosidase, was recovered. Ortho-nitrophenyl-β-galactoside (ONPG; Thermo),
which β-galactosidase cleaves into the yellow product o-nitrophenol (ONP),62 was then added to
the supernatant at a final concentration of 0.8 mg/mL and absorbance was monitored at 405 nm
every 5 min for 1 hr. Values reported are an average of the one hour points for three trials; error
bars represent standard error.
Potassium Efflux. B. subtilis was grown to mid-logarithmic phase (OD600=0.4-0.6) in
LB 5.5, washed and resuspended at a concentration of 1 x 108 cfu/mL in MES 5.5. Cells were
then mixed with ClavA or ClavA-Zn2+ at twice their respective MBCs to yield solutions
containing 5 x 108 cfu/mL B. subtilis and peptides at the MBC. The potassium concentration was
then monitored every 10 min for 1 hr using a potassium sensitive electrode and reference
electrode (MI-442 and MI-402; Microelectrodes, Bedford, NH, USA) connected to a pH meter
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(Orion Star A111; Thermo) measuring potential in mV. Cells were then lysed using a
combination of freeze thaw cycles and sonication, and the potential of the resulting solution was
used as an internal positive control. Percentages were calculated using a blank bacteria sample
with no peptide as a negative control.
Confocal Fluorescence Microscopy. E. coli cultures were grown to an OD600~1.0 (1 x
109 cfu/ml) in LB 5.5, then washed and suspended in MES 5.5 containing 20 mM glucose.
Aliquots were incubated with 8 μM of either ClavA-TMR or ClavA-TMR-Zn2+ for 1 hr at room
temperature. This concentration was used for both treatments because higher ClavA-TMR
concentrations would cause oversaturation of the image. Mixtures were then spun down and
resuspended in fresh MES 5.5 with 20 mM glucose prior to imaging to remove any unbound
peptide. Cells were imaged on a Nikon A1R spectral confocal microscope using a 60X oil
immersion lens.
In Vitro DNA Cleavage. Samples were prepared by mixing 10 μM base pair pUC19
with 1μM ClavA-Zn2+, 1 μM ClavA with 20 μM diethylenetriaminepentaacetic acid (DTPA) or 2
μM Zn2+ in MES 5.5. Mixtures were allowed to stand at room temperature for indicated times,
then were stopped using 3x loading dye containing 1 mM EDTA prior to loading on the gel.
After all samples at various time points were prepared, the samples were loaded on a 1% agarose
gel containing ethidium bromide, and the gel was run at 100V for 90 min. Gels were imaged
using a Bio-Rad GelDoc XR+ Imager and quantified using Image Lab 5.0 software. A correction
factor of 1.47 was applied to the data for supercoiled DNA to account for the difficulty of
staining with ethylene bromide.93
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Chapter 3 – Clavanin A, Zinc metallonuclease effective against gram negative
pathogens

Adapted from: Juliano, S. A.; et. al., A Potent Host Defense Peptide Triggers DNA Damage and is Active
against Multi-Drug Resistant Gram-Negative Pathogens. Manuscript Submitted

3.1 – Introduction
The worldwide emergence of antibiotic-resistant bacteria has endangered the
efficacy of antibiotics. Some frightening projections estimate that antibiotic-resistant
bacteria will result in the death of 2.4 million people annually by 2050, costing in excess
of $3 billion per year.1 Hospital acquired infections are responsible for the death of over 1
million patients per year in the US alone, with the primary offenders including the so called
ESKAPE

pathogens

(Enterococcus

faecium,

Staphylococcus

aureus,

Klebsiella

pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter
species).2-3 Isolates of each of these bacterial species have been reported to contain multiple
mechanisms for antibiotic resistance, setting the stage for the fulfilment of these
projections.4 Gram-negative bacteria, in particular, have shown an alarming prevalence of
antibiotic resistance. For example, particular species of Acinetobacter and Pseudomonas
are showing resistance to all available antibiotics, and carbapenem resistance genes from
Klebsiella spp. have spread to gram-negative bacteria worldwide.5-6 With so many bacteria
showing resistance, even to some of the antibiotics of last resort, the need for novel
therapeutic compounds to combat the problem is greater than ever.
In recent years, host defence peptides (HDPs) have become of great interest as tools
to supplement our antibiotic arsenal. Their beneficial qualities include broad spectrum
activity

and

low

incidence

of

resistance

development.

Clavanin

A

(ClavA,

VFQFLGKIIHHVGNFVHGFSHVF-NH2), a 23-residue HDP isolated from the hemocytes
of the solitary tunicate Styela clava, has shown great promise as a novel therapeutic against
a wide range of bacterial pathogens. In vitro studies of murine wound infection models
showed improved healing and eradication of bacteria, while in systemic infection models,
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ClavA treatment resulted in increased survival for both Escherichia coli and
Staphylococcus aureus infected mice.7 In addition to this, ClavA has also proven effective
against biofilms, preventing the formation of E. coli and S. aureus biofilms and perturbing
preformed biofilms of K. pneumoniae.8
In our own studies of ClavA, we found evidence for a Zn(II)-regulated intracellular
mechanism of action (MoA), which we hypothesized to involve damage to bacterial DNA.9
This hypothesis was supported by evidence of in vitro DNA cleavage by ClavA-Zn(II), and
inhibition of ClavA activity in E. coli strains lacking the ability to transport Zn(II) ions.
These results represent a novel MoA for zinc-binding HDPs, most of which have been
reported to sequester Zn2+ to keep this essential micronutrient away from invading
pathogens.10
Zinc, the second most abundant trace metal in human cells after iron, is an important
micronutrient for many cellular processes in mammalian cells including DNA and RNA
synthesis, and membrane stabilization.11-13 More importantly, Zn(II) deficiencies have been
found to be important in several chronic diseases, including diabetes,

and

neurodegenerative diseases, as well as increasing susceptibility to many infectious diseases,
including HIV, malaria, and bacterial infections. 14 Important immune functions, such as
phagocytosis and intracellular killing are affected by zinc deficiency. 15 Zinc(II) ions are a
common weapon used by eukaryotes to combat bacteria. For example, zinc levels in blood
serum of infected mice can reach up to 900 μM.16 Zinc is also trafficked into the phagosome
of murine macrophages infected with mycobacteria. When infected with Mycobacterium
tuberculosis, phagosomal zinc concentrations reach of up to 459 μM, after 24 hr post
infection.17 Although the concentration of zinc(II) ions reach very high micromolar levels,
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even higher concentrations seem to be needed for it to have a bactericidal effect. Zinc
concentrations of 1 mM have been shown to abolish the growth of wild-type Streptococcus
pneumoniae, while 250 μM Zn(II) only delays its growth. In S. clava hemolymph the zinc
concentration was found to be 26.7 ± 7.1 μM, though it is likely that the local concentration
within phagocytic cells is much higher.9
As a result of elevated zinc concentrations, ClavA based treatments could enhance
the body’s natural infection response, allowing for treatments that work in tandem with our
bodies’ natural defences. It is important, however, to first understand exactly how ClavA
and zinc ions are working together to eliminate bacterial infections, as such knowledge will
allow for further optimization of this natural framework.
3.2 – Results
Zn(II) potentiates the antimicrobial activity of ClavA against Gram-negative pathogens
We have previously shown that when ClavA is combined with Zn(II), the activity of the
peptide against E. coli is increased. In order to determine if this activity potentiation is unique to
E. coli, we tested the activity of ClavA and ClavA-Zn(II) against the gram-negative ESKAPE
pathogens, including some multi-drug resistant clinical isolates. Gram-negative pathogens are of
great interest due to the difficulty of penetrating their double membrane structure, with the outer
membrane containing LPS and lipid A which aid in defending the bacteria against cationic
AMPs.18-19 Additionally, gram-negative bacteria contain efflux pumps that not only remove small
molecules from the cytoplasm and periplasm, but also many AMPs. The results of testing ClavA
and ClavA-Zn(II) against gram-negative bacteria are summarized in Table 3-1. In every case we
observed a decrease in the minimum inhibitory concentration (MIC) upon incubation of the peptide
with Zn(II) at double the peptide concentration, which correlates to an increase in activity. This
75

improvement in activity can even be seen in multi-drug resistant ESKAPE pathogen clinical
isolates and multi-drug resistant E. coli, though the Zn(II)-based potentiation against E. coli AR
Bank #0114 is not quite as pronounced as for the wild type E. coli.20 The activity of ClavA against
P. aeruginosa and K. pneumoniae was above the limit of detection of the experiment, so they can
only be said to show at least 8-fold and 4-fold improvements, respectively, while activity against
A. baumannii and Enterobacter cloacae each improved 4-fold upon the addition of Zn(II). While
none of these quite reached the 16-fold improvement seen against E. coli, the modest activity
potentiation observed is still very promising for the effectiveness of ClavA-Zn(II) against other
gram-negative pathogens. Additionally, the fact that ClavA-Zn(II) showed improvement against
multi-drug resistant clinical isolates provides further evidence of how effective ClavA is as an
antimicrobial compound.
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Table 3-1
Clavanin A minimum inhibitory concentrations against various wild type and drug
resistant bacteria.
Bacterial Strain

ClavA MIC

ClavA-Zn(II) MIC

E. coli MG1655 a

64 μM

4 μM

E. coli TD172

8 μM

2 μM

E. coli AR Bank #0114 b

64 μM

8μM

K. pneumoniae AR Bank #0113 b >256 μM

128 μM

A. baumannii Naval-17 b

32 μM

8 μM

P. aeruginosa PA01

>256 μM

64 μM

P. aeruginosa AR Bank #0229 b

>256 μM

64 μM

E. cloacae AR Bank #0136 b

256 μM

64 μM

a Wild type, Taken from reference 9
b Multi-drug resistant clinical isolate
These results indicate a strong synergy between ClavA and zinc ions when coupled with
the MIC values for Zn(II) against these pathogens (Table 3-2). The lowest MIC recorded for Zn(II)
was 1mM against E. coli MG1655 and A. baumannii Naval-17, which is still double the highest
zinc concentration used in any of the ClavA-Zn(II) MIC measurements. In many cases, the MIC
of Zn(II) with ClavA is a full order of magnitude lower than the MIC of Zn(II) alone. This
improvement in activity clearly indicates strong synergism between ClavA and Zn(II) ions.
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Table 3-2
ClavA Zn(II) Antimicrobial Synergy
Bacterial Strain

Zn2+ MIC

FIC

Definition a

E. coli MG1655

1024 μM

0.070

Synergy

E. coli TD172

4096 μM

0.251

Synergy

E. coli AR Bank #0114

2048 μM

0.133

Synergy

K. pneumoniae AR Bank #0113

8192 μM

0.281

Synergy

A. baumannii Naval-17

1024 μM

0.266

Synergy

P. aeruginosa PA01

2048 μM

0.187

Synergy

P. aeruginosa AR Bank #0229

2048 μM

0.187

Synergy

E. cloacae AR Bank #0136

2048 μM

0.313

Synergy

a Synergy is defined as an FIC ≤ 0.5

Clavanin A shows nuclease activity in cellulae
Although we have shown evidence that ClavA-Zn(II) can damage DNA in an in
vitro assay,9 evidence for this damage in cellulae is absent. In order to prove that this
activity occurs within living bacteria, we employed E. coli TD172 (ΔrecA::kan) in which
the gene for the DNA repair protein RecA has been deleted. Treatments which lead to DNA
damage will thus be more potent as the ΔrecA strain is less capable of repairing the damage.
Both ClavA and ClavA-Zn(II) show improved activities against E. coli TD172 as compared
with wild type E. coli (Table 3-1), though the two-fold increase in activity for ClavA-Zn(II)
does not represent a significant change. It is likely that the range of 2-4 μM represents the
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absolute minimum amount of ClavA-Zn(II) required to inhibit growth through DNA
cleavage. The fact that both ClavA and ClavA-Zn(II) approach this minimum amount in
the ΔrecA E. coli provides more concrete evidence that DNA damage is important to the
activity of ClavA.
While MICs against E. coli TD172 provide evidence that E. coli which are incapable of
repairing DNA damage are more susceptible to ClavA and ClavA-Zn(II), these results do not
definitively prove that DNA damage is occurring, nor can they quantify the amount of damage.
With that aim in mind, we employed the terminal deoxynucleotidyl transferase dUTP nick end
labelling (TUNEL) assay, which fluorescently labels strand breaks to allow for quantification. As
can be seen in Figure 3-1, the DNA damage caused by ClavA-Zn(II) is steady across all time points
at about 75% higher than baseline, whereas ClavA alone takes more time to reach the same level,
with the two showing statistically identical levels of damage after 4 hours. It is likely that ClavAZn(II) is causing immediate DNA damage due to the abundance of Zn(II) ions available for
binding, while ClavA alone takes longer to achieve statistically similar levels due to the need to
scavenge zinc ions from the E. coli themselves. These results provide proof that the ClavA-Zn(II)
complex is capable of damaging DNA in intact bacterial cells.
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Figure 3-1
TUNEL assay results for ClavA and ClavA-Zn showing the fold increase in DNA
damage over the untreated control.

Further evidence for DNA as the target of ClavA-Zn(II) can be observed in the MIC values
obtained using the all D-amino acid form of ClavA. The MICs observed for D-ClavA and DClavA-Zn(II) against E. coli MG1655 were both found to be 32 μM, showing none of the
potentiation usually observed for the zinc containing peptide. Often, HDPs with achiral targets,
such as the membrane, will show minimal change in MIC when D-amino acids are used, whereas
those with chiral targets, like DNA, will see diminished activity.21-24 The change in MIC from 4
μM to 32 μM for ClavA-Zn(II) is indicative of a peptide with a chiral target, further promoting the
likelihood of DNA as the target molecule.
QM/MM allows for the determination of the nuclease mechanism of ClavA-Zn(II)
The electrostatic surface potential and helical wheel projection of ClavA displaying its
amphipathic character are shown in Figure 3-2. In the α-helical conformation, the hydrophilic and
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lipophilic residues are located on opposite sides of the peptide. Every pose provided by molecular
docking show that the positively charged hydrophilic side of ClavA binds to the negatively charged
major groove of DNA, while the hydrophobic side of ClavA is exposed the water solvent. In the
lowest energy docked pose, ClavA occupies the major groove of DNA and interacts through
multiple hydrogen bonds and CH-π interactions and the Zn(II) ion is located ~8 Å away from the
closest phosphate group of DNA. During the MD simulations using this pose, the Zn(II) ion rapidly
approaches the phosphate group of DNA and binds the negatively charged oxygen atom in a
monodentate fashion. In the equilibrated structure, residues Lys7, His10, His11, Asn14, His17 and
Ser20 of ClavA are responsible for retaining its position in the major groove of DNA through
hydrogen bonding with phosphate groups, while His10 and His17 associate through CH-π
interactions with cytosine base pairs. These interactions also help to maintain the alpha helicity of
the fragment of ClavA that is inserted in the major groove of DNA. The small root-mean-squarefluctuations (RMSFs) support the overall stability of the α-helical structure of ClavA (Figure 3-3).
In the most representative structure derived from MD simulations, the Zn(II) ion is found to
interact with His17, His21, phosphate group (in the monodentate form) and three solvent water
molecules (Figure 3-4).
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Figure 3-2
(a) Electrostatic surface potential and (b) helical wheel projection of ClavA showing the
amphipathicity of the peptide.

Figure 3-3
Root-mean-square-fluctuations (RMSFs) in the ClavA-Zn complex.
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Figure 3-4
The MD equilibrated structure of the ClavA-Zn complex used for the QM/MM (ONIOM)
calculations. Some hydrogen atoms and solvent water molecules were omitted for clarity.
Nitrogen in blue, phosphorus in orange and oxygen in red.

This structure was subsequently utilized to investigate the mechanism of DNA hydrolysis
by ClavA through hybrid two-layer (QM/MM) ONIOM calculations. In the mechanism, the
Zn(II) ion is proposed to be involved in the Lewis acid activation, nucleophile activation and
generation of a good leaving group25-29. In the optimized structure of the reactant (R), Zn(II) is
coordinated to two histidine residues (His17 and His21), one hydroxyl ion (-OH), a water
molecule and a phosphate group of DNA (Figure 3-5). The binding of a water molecule to the
Zn(II) ion and interactions with another water and phosphate groups significantly lowers its pKa
value. This lowering of the pKa of water to generate a hydroxyl group through metal
coordination and hydrogen bonding is a common feature of metallohydrolases30-31. Additionally,
two water molecules (W1 and W2) are also present at the active site. These water molecules form
a hydrogen bonding network between the Zn(II) bound OH group and the phosphate groups
including Cy10 and Cyt11 of DNA (Figure 3-4). Furthermore, due to the Lewis acidity of the Zn
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ion, the scissile P-O bond (1.53 Å) of DNA in R is elongated by 0.05 Å in comparison to the
bond (1.48 Å) in its free form. In the first step, the Zn(II) bound OH functions as a base and
abstracts a proton from W2 through the bridging W1 water, i.e. the W2→W1→OH(Zn) pathway.
This chain of proton transfer causes the formation of a nucleophile (-OH) close to the phosphate
group, which simultaneously attacks the electrophilic phosphorus (P) atom and cleaves the
scissile phosphoester [P-O(Cyt10)] bond (Figure 3-5). This concerted process occurs with a
barrier of 30.2 kcal/mol and the optimized transition state (T1) is shown in Figure 3-5. This is
the rate-limiting step of the entire mechanism. The reason for this high barrier is the low acidity
of W2 in the major grove. The removal of W1 in the model significantly increases the barrier for
this process by 6.2 kcal/mol i.e. 36.4 kcal/mol from the corresponding reactant. Additionally, a
direct attack by the Zn(II) coordinated -OH nucleophile, without the assistance of both W1 and
W2, takes place with a barrier further higher by 11.1 kcal/mol i.e. 41.3 kcal/mol from the
reactant. These results show that in this ligand environment the Zn(II) bound -OH is a weak
nucleophile. Furthermore, formation of the pentavalent phosphorane intermediate created by the
direct Zn(II)-OH nucleophilic attack is endothermic by 45 kcal/mol. In the intermediate (In1),
formed through T1, one of the DNA strands is broken to create a negatively charged cytosine
(Cyt10O-) fragment (Figure 3-5). Since this charged fragment is not a good leaving group, the
formation of In1 is endothermic by 20.7 kcal/mol from R. Due to the bulkiness of the Cyt10Ofragment, it cannot move and accept a proton from the -OH nucleophile that is now coordinated
to the P atom. Therefore, the neutralization of this fragment requires two additional steps. In the
next step, from In1 the proton from the nucleophile through W1 is transferred to the nonesterified O1 atom. This step occurs with a small barrier of 1.7 kcal/mol from In1 and the
optimized transition state (T2) is shown in Figure 3-5. The intermediate (In2) formed in this step
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is exothermic by 23.2 kcal/mol from the reactant R. In In2, the Cyt10 fragment is ideally located
to abstract the O1H proton. In the final step, this transfer takes place with an extremely low
barrier of 0.5 kcal/mol from In2 i.e. 22.7 kcal/mol from R (Figure 3-5). The product (P) with the
neutral form of the Cyt10 fragment is exothermic by 30.7 kcal/mol.
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Figure 3-5
The proposed mechanism for the DNA hydrolysis by the ClavA-Zn complex via activation
of secondary coordination sphere water molecules.

3.3 – Discussion
In this study we were able to more definitively prove a hypothesis we presented in our
previously published work,9 namely that not only is the antimicrobial activity of the HDP ClavA
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potentiated by the presence of zinc ions, but also that ClavA-Zn(II) is capable of functioning as a
metallonuclease within live bacteria. We were also able to propose a probable mechanism for the
cleavage of DNA through the application of QM/MM. This mechanism is particularly novel, as
most metallonucleases cleave DNA via activated water molecules in the primary coordination
sphere, whereas ClavA-Zn(II) utilizes a secondary coordination sphere water molecule to cleave
the phosphoester bond in the DNA backbone.
In addition to all of the mechanistic work on ClavA, we were also able to expand the
scope of the Zn(II) based potentiation of ClavA to encompass not only E. coli, but also all of the
gram-negative ESKAPE pathogens, including some multi-drug resistant clinical isolates. These
results seem to imply that ClavA-Zn(II) will show a similar potentiation against all gramnegative pathogens. This finding is of particular importance as gram-negative bacteria are
particularly difficult to treat with conventional methods due to their double membrane
structure.18 Gram-negative bacteria have a significantly lower success rate than gram-positive
bacteria when it comes to drug screening tests, with P. aeruginosa reporting up to 1000-fold
fewer successes than gram-positive pathogens.32 The successful application of ClavA-Zn(II) to
the treatment of these difficult pathogens could help to encourage the development of peptidic
antibiotics for the treatment of gram-negative infections, as well as the development of new
strategies for bypassing the particularly resilient gram-negative membrane.
Many transition metals, when presented in sufficient quantities, have proven to be toxic
to bacteria, and zinc is no exception. We have shown that the MIC values for Zn(II) against the
bacteria used in this study are all in the low millimolar range, while in the MIC experiments for
ClavA-Zn(II) the highest concentration of Zn(II) used is 512μM. When fractional inhibitory
concentration (FIC) is calculated it is clear that the interaction of ClavA with Zn(II) ions is
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synergistic, with bacterial growth inhibition occurring at much lower concentrations than for
each alone.
While we have established that ClavA-Zn(II) is able to function as a nuclease in cellulae,
there are still some questions that still need answers. It is unclear from the results of this study
and previous work exactly how ClavA is able to cross the membrane.9, 33 This information will
be important if peptide-based antibiotics are to be engineered for future use. Additionally, there
is still a discrepancy regarding the mechanism of action for ClavA, as publications from three
independent laboratories identify the membrane as the target for this HDP.33-35 Despite all that
has already been discovered for this remarkable system, it is clear that there is more to be done
before we can close the book on ClavA.
3.4 – Methods
Bacterial Culture Conditions
Bacteria treated under low pH conditions were grown in LB media containing 50 mM
MES buffer at pH 5.5. For the neutral pH experiments, bacteria were grown and treated in
standard MHB media at pH 7.4. Cells were incubated at 37℃ and 234 rpm to mid-log phase
(OD600 = 0.4-0.6).
Minimum Inhibitory Concentration Determination
Minimum Inhibitory Concentrations (MICs) for ClavA and ClavA-Zn(II) were
determined via the broth microdilution method, which has been previously described.36 Briefly,
bacteria were grown to mid-log phase (OD600= 0.4-0.6), diluted to a final concentration of 1x106
cfu/mL and treated with serially diluted peptide for 18 hr. All of the growth media used
contained 50mM MES buffer at pH 5.5. MIC was determined as the concentration of peptide at
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which no growth could be visually observed. The data presented represent the mode of three
trials. For all experiments containing ClavA-Zn(II), the peptides were incubated with ZnCl2 for
30 min at room temperature at 2x the maximum concentration used, with the maximum zinc
concentration of any of these assays being 512 μM.
When determining MIC values for Zn(II), a similar process was utilized. Diluted bacteria
were treated with ZnCl2, and MICs correspond to the lowest concentration at which no growth
could be observed visually. Values were measured at pH 5.5 and 7.4, and were found to be
identical. Results represent the mode of three trials.
TUNEL Assay
The TUNEL assay has been described previously.37 Briefly, an overnight culture of E. coli
was washed in PBS. The cells were then treated with MIC concentrations of ClavA and ClavAZn(II), with aliquots removed at 1 hr, 2 hr and 4 hr. A negative control was performed with PBS
and a positive control with 1.5% H2O2. After incubation, cells were fixed and dyed, then propidium
iodide and fluorescein labeled cells were measured via flow cytometry. Data presented represent
the average of three trials, and the error bars are standard error from mean.
Computational Details
Molecular Dynamics (MD) simulations
The structure of ClavA was obtained from the protein data bank (PDB ID: 6C41).38 The
initial ClavA-Zn structure in which His17 and His21 were coordinated to the Zn ion was build and
energy minimized using the YASARA software.39 The CAAGACGGCCCCGGCCC nucleotide
sequence40 of E. coli TD172 DNA was built using the Avogadro software41. The HDOCK
webserver was used to explore the binding poses of the ClavA-Zn complex to DNA.42 In all the

89

docked structures, ClavA-Zn was located in the major groove of DNA. Two different ClavA-Zn
binding poses were used as the starting structures for molecular dynamics (MD) simulations i.e.
(1) ClavA-Zn is bound in a perpendicular manner inside the major groove of DNA and (2) ClavAZn is bound parallel to the major groove of DNA (Figure 3-6). All 200 ns all-atom MD simulations
in aqueous solution were performed using the GROMACS-4.5.643 program utilizing the
CHARMM3644 force field. This force field was reported to reproduce the key structural features
of ClavA and ClavA-Zn in our previous work.45 The ClavA-Zn--DNA complex was placed in the
cubic box of 10 × 10 × 10 nm dimension. The shortest distance from the edge of the box to the
surface of the complex was 1.0 nm. Particle Mesh Ewald method46 was used to compute the
electrostatic interactions and for both Coulombic and van der Waals interactions 1.2 nm cutoff
distance was maintained. TIP3P47 water was used as a solvent and Na+ and Cl- were added to
neutralize and to maintain the physiological ion concentration (154 mM) of the system. The
starting structures for MD simulations were energy minimized for 3000 steps using the steepest
descent method. The simulations were performed using a constant number of particles (N),
pressure (P) and temperature (T) i.e. NPT ensemble. SETTLE48 algorithm was used to constrain
the bond length and angle of the water molecules and LINCS49 algorithm was employed to
constrain the remaining bond lengths. The trajectories were computed for each model with a time
step of 2 fs. Cluster analysis was utilized to obtain the most representative ClavA-Zn--DNA
structure from the MD simulations. The ClavA-Zn and DNA binding energies were calculated by
utilizing the Molecular Mechanics Poisson–Boltzmann Surface Area (MM-PBSA) method.50 A
comparison of the binding energies shows that which shows that the structure in which ClavA was
bound in a perpendicular fashion inside the major groove of DNA is 37.0 kcal/mol lower in energy
than the second structure (Figure 3-6).
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Figure 3-6
Two MD equilibrated conformations of the ClavA-Zn--DNA complex. The
perpendicular arrangement has a lower energy.

QM/MM simulations
All hybrid two-layer QM/M (ONIOM) calculations were performed using the
Gaussian 09 (ONIOM) software package.51 ONIOM utilizes a subtractive method in which
the MM energy [EMM (model)] of the QM (model) part is subtracted from the sum of the
QM energy of the model [EQM (model)] and MM energy [EMM (real)] of the whole (real)
system,

i.e., EONIOM (QM/MM)

= EQM (model)

+ EMM (real)

‐ EMM (model).

This
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subtraction method corrects the artefacts introduced by the link atom. 52 The ONIOM
optimization procedure uses macro/microiterations53 and the electrostatic interactions
between the QM and the MM part were treated by mechanical embedding (ME). The QM
region comprised of Zn(II) ion, His17, His21, two cytosine nucleotides, a hydroxyl ion and
one to three water molecules (depending on the reaction mechanism) as shown in Figure 34. The remaining part of the system was included in the MM layer. The ClavA-Zn--DNA
complex was surrounded with explicit water molecules (2139 water molecules; MM layer)
to stabilize the highly negative charge of DNA. The QM layer was optimized without any
geometric constraints using the hybrid B3LYP54 exchange-correlation functional. The
Lanl2dz basis set (for the Zn atom) with the corresponding Hay-Wadt effective core
potential (ECP)55 and the 6-31G(d) basis set (for the remaining atoms in the QM layer)
were used. The MM layer was modeled using the AMBER force field.56-57 The energies of
the optimized structures were further improved by performing single-point calculations
using the large basis sets e.g. Lanl2tz for Zn and triple-zeta 6-311+G(d,p) for other atoms.
Hessians were calculated at the same level of theory as the optimizations to confirm the
nature of the stationary points along the reaction coordinate. The transition states were
confirmed to have only one imaginary frequency corresponding to the reaction coordinates.
The transition states were confirmed to have only one imaginary frequency corresponding
to the reaction coordinates. Zero-point vibrational, thermal and entropy corrections were
added to the final energies (at 298.15 K and 1 atm). Helical wheel projection of ClavA was
obtained from NetWheel online webserver.58 VMD59, YASARA39, ChemDraw and
Chimera60 programs were used for the visualization of the MD trajectories and preparation
of the figures used in this study.
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Chapter 4 – Three Strategies in Motion: Bacterial Cytological Profiling Elucidates
the Mechanisms of Action for Clavanin A

Adapted from: Juliano, S. A.; et. al., A Potent Host Defense Peptide Triggers DNA Damage and is Active
against Multi-Drug Resistant Gram-Negative Pathogens. Manuscript Submitted

4.1 – Introduction
Up to this point, our studies of Clavanin A (ClavA, VFQFLGKIIHHVGNFVHGFSHVFNH2), the 23-residue, tunicate derived, host defense peptide (HDP), have resulted in a thorough
understanding of the Zn2+ based nuclease mechanism of action (MoA), a novel mechanism for
zinc binding peptides. This, however, presented some confusion due to the fact that studies from
three independent laboratories provided evidence that ClavA exerts its activity through
disruption of the bacterial membrane.1-3
ClavA was discovered as a member of the Clavanin family of HDPs isolated from the
hemocytes of the tunicate Styela clava. Lehrer and co-workers, who first isolated the Clavanin
family, were able to demonstrate a pH dependent MoA for ClavA with the peptide showing
greater activity at lower pH values.2 This idea was later expanded upon by van Kan et al. who
proposed two mechanisms for ClavA acting at different pH values.1 At neutral pH (7.4) it was
concluded that the MoA of ClavA involves nonspecific pore formation driven by hydrophobic
effects, while at low pH (5.5) the activity was hypothesized to originate from increased
permeability of the membrane to small ions, likely the result of interaction between ClavA and a
membrane ionophore or ATP synthase.1
ClavA is a very good candidate for drug discovery and development as in vitro studies in
murine wound infection models showed improved healing and eradication of bacteria.5 In
systemic infection models, ClavA treatment resulted in increased survival for both Escherichia
coli and Staphylococcus aureus infected mice. In addition to this, ClavA has also proven
effective against biofilms, preventing the formation of E. coli and S. aureus biofilms and
perturbing preformed biofilms of Klebsiella pneumoniae.6 ClavA has also been conjugated to the
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surface of iron oxide nanoparticles and coated onto central venous catheters.7 ClavA-Iron oxide
coated catheters were capable of reducing adhesion of both gram positive (~50%) and gram
negative (70-90%) bacteria and modestly reducing the amount of planktonic bacteria (up to 20%)
as well.
Despite the apparent suitability of ClavA as a potential therapeutic, our limited
understanding of its chemistry makes it impossible to predict what changes in its sequence will
result in more potent antimicrobial activity, a problem not limited to ClavA alone.8-16 Thus, there
is need for a technique capable of quickly and inexpensively identifying the MoA of HDPs so
that further studies can be targeted to obtaining more precise information on how a given peptide
kills or inhibits the growth of bacteria. With this information regarding HDP mechanisms of
action in hand, it becomes much more likely that antibiotics based on HDPs could help to stem
the growing tide of antibiotic resistance currently plaguing society.
If novel antibiotics are going to be designed based off of the framework provided by
HDPs it is important to have a firm understanding of how natural HDPs are capable of fighting
bacterial and fungal infections. The current paradigm for identifying the mechanism of action of
newly discovered HDPs involves a battery of tests which often result in only being able to
determine if a peptide is membrane active or internal targeting. The application of bacterial
cytological profiling (BCP) to the study of HDPs will streamline the determination of
mechanism of action, resulting in more targeted studies aimed at fine tuning the precise target for
the peptide.17 This knowledge will then allow for the future development of peptidic antibiotics
to stem the growing tide of multi-drug resistant bacteria. Through the application of BCP to
ClavA we have proposed the most complete picture of the activity of ClavA to date.
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4.2 – Results
Phenotypic Analysis Reveals Multiple ClavA Mechanisms of Action
Despite the compelling evidence indicating that ClavA is capable of cleaving DNA
in the presence of zinc ions, it cannot be ignored that almost all of the published research
on the HDP indicates that it is membrane active.1-3, 18 We have shown previously that ClavA
has antimicrobial activity in the absence of zinc ions, which would indicate that ClavA has
at least two mechanisms of action depending on the environment of the peptide. In order to
further explore the mechanisms employed by ClavA, we hypothesized that bacterial
cytological profiling (BCP) will allow for the observation and differentiation of each of the
ClavA mechanisms of action. BCP is based on the idea that antibiotics that act on the same
pathway or target will likewise cause the same phenotypic changes in treated bacteria.17
This technique has been previously applied to the study of the MoA for small molecule
antibiotics and anticancer metal-ligand complexes.19, 20
The study of the antimicrobial effect of any molecule via BCP begins with
phenotypic analysis of treated cells. The first step in this process is to collect and analyse
micrographs of E. coli treated with ClavA. The morphology of the bacterial membranes
was measured via staining with FM 4-64 (Figure 4-1, red) and its permeability reported by
SYTOX green (Figure 4-1, green), a cell impermeable DNA dye. The cell permeable DNA
stain DAPI (Figure 4-1, blue) was also used to report on nucleoid morphology. These
images are analysed for size and shape of the membrane and nucleoid as well as the relative
intensity of the DNA dyes.
After treating E. coli with ClavA for 60 minutes at pH 5.5, we observed two distinct
phenotypes (Figure 4-1C). The first phenotype, indicated by the solid white box, were
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longer than untreated E. coli (Figure 4-1A), but maintained the same overall appearance
with a ring of red for the membrane and blue DNA inside. Cells displaying the second
phenotype, indicated by the dashed white box, maintained a similar overall size to untreated
cells, but with a diffuse red signal throughout and with DNA stained both blue and green.
We called these two phenotypes Type A1 and Type A2, respectively, due to the acidic pH
at which they are observed. Approximately 60% of the cells show Type A1 damage and the
remaining 40% Type A2 after 60 minutes of treatment (ClavA damage types are
summarized in Table 4-1). Based on these results we conclude that, at low pH, ClavA is
actually working via two different mechanisms of action.
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Figure 4-1
Micrographs of E. coli that have been (A) untreated, or treated with (B) ClavA for 30 min,
(C) ClavA for 60 min, (D) ClavA for 120 min, (E) ClavA-Zn(II) for 60 min, and (F) ClavA
for 60 min at neutral pH. Scale bars are 5 μm long. Solid white boxes indicate ClavA Type
A1, while dashed white boxes indicate Type A2.
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We hypothesized that these two mechanisms of bacterial damage were based on
exposure time to ClavA. To test this, we modified the treatment time from the original 60
min to 30 and 120 min, represented by Figure 4-1B and 4-1D, respectively. After 30 min
of treatment, the predominant MoA for ClavA is Type A1, with about 80% of cells falling
into that category. The ratio flips at 120 min, with 75% of the cells exhibiting the Type A 2
phenotype. This would indicate that the initial interaction of ClavA with E. coli results in
Type A1 damage, with Type A2 appearing after, and possibly as a result of, Type A1.
Since ClavA is potentiated by Zn(II) at low pH, we next determined if and how the
addition of Zn(II) affected the phenotype of the treated E. coli. As can be seen in Figure 41E, ClavA-Zn(II) treatment results exclusively in damage resembling Type A 2. The visual
similarities between E. coli treated with ClavA-Zn(II) and Type A2 damage point to the
likelihood that these two mechanisms are the same and that the Type A2 MoA results from
scavenging Zn(II) ions from E. coli or the media.
Next, we determined if and how these mechanisms differ from the activity of ClavA
at neutral pH since van Kan et al. postulated a different MoA under those conditions,
namely nonspecific pore formation.1 Figure 4-1F shows cells treated with ClavA at pH 7.4.
It can be observed that these cells are longer than either untreated or ClavA Type A 1
damaged E. coli, and that most (~88%) of these cells have two nucleoids (Figure 4-1F).
The MoA that resulted in this visually distinct phenotype is referred to as ClavA Type N,
due to the neutral pH at which this phenotype appears.
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Table 4-1
A Summary of the ClavA Mechanisms of Action.
Damage Type

General Features
Slightly longer than untreated E. coli, normal ring-shaped

Type A1

membrane
Diffuse membrane staining, blue and green stained DNA

Type A2

Longer than Type A1, most cells have two nucleoids, normal
Type N

membrane

Identification of Mechanisms of Action through Principal Component Analysis
For a more quantitative approach to data analysis, we employed Principal
Component Analysis (PCA), which is a statistical treatment that reduces the dimensionality
of a large dataset, while minimizing the loss of variance. In this procedure, the set of
measurements of possibly correlated variables are orthogonally transformed into values of
uncorrelated variables, called principal components. The first principal component reflects
the variable with the highest variance, followed by the second principal component with
the second highest variance, and so on. Commonly, the values of the first, second, and third
principal components are used for presenting the visual 2D and 3D plots. We have elected
to use the 2D plot as the variance in the third dimension was minimal.
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Figure 4-2 shows a PCA plot of the data pertaining to the various mechanisms of
action for ClavA presented above (Data collected for all treatments and used for PCA can
be found in Table 4-2 and 4-3). It is clear from the plot that Type A1 and Type N are found
in different regions of the plot, while Type A 2 and ClavA-Zn(II) cluster together. These
results corroborate what was found through phenotypic analysis, namely that Type A 1,
Type A2, and Type N mechanisms are all different, and that the MoA corresponding to
Type A2 is the same as that of ClavA-Zn(II).

Figure 4-2
PCA plot of the ClavA treatments with model AMPs. The boxes indicate treatments which cluster
together.
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Table 4-2
Average morphology measurements of treated bacterial membranes
Area

Perimeter

Length

Width

(μm2)

(μm)

(μm)

(μm)

3.787

8.532

3.287

1.239

0.658

1.333

3.272

7.933

2.961

1.072

0.667

1.229

5.557

11.336

4.641

1.278

0.550

1.873

3.443

7.574

2.823

1.173

0.752

1.063

Buforin II

3.656

8.399

3.328

1.160

0.653

1.000

Indolicidin

4.683

9.566

3.798

1.211

0.652

1.226

Ixosin

2.448

6.687

2.444

1.046

0.692

1.271

Magainin 2

6.602

13.018

5.439

1.285

0.503

1.600

Piscidin 1

5.510

11.785

4.792

1.172

0.516

1.342

Piscidin 3

4.996

10.914

4.436

1.145

0.539

1.449

Treatment

Nucleoids/
Circularity
Cell

Clavanin A
Type A1
Clavanin A
Type A2
Clavanin A
Type N
ClavAZn(II)
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Table 4-3
Average morphology measurements of treated bacterial nucleoids

Area

Perimeter

Length

Circularity
(μm )

(μm)

(μm)

Corrected

SYTOX

DAPI

Intensity

Intensity

Width

Treatment
2

Corrected
(μm)

Clavanin A
1.288

4.845

1.967

0.693

0.677

1.285

2.869

1.746

5.641

2.083

0.845

0.688

15.165

3.626

1.425

5.068

1.919

0.775

0.701

1.005

0.842

2.476

6.643

2.480

0.945

0.702

15.644

2.430

Buforin II

1.712

5.868

2.339

0.739

0.635

1.280

1.674

Indolicidin

1.633

5.965

2.535

0.609

0.582

1.023

1.929

Ixosin

0.738

3.696

1.364

0.652

0.678

5.096

1.526

Magainin 2

2.173

7.038

2.886

0.743

0.559

1.069

1.349

Piscidin 1

1.816

6.838

2.902

0.675

0.519

1.108

1.299

Piscidin 3

1.852

6.270

2.371

0.735

0.604

1.122

0.929

Type A1
Clavanin A
Type A2
Clavanin A
Type N
ClavAZn(II)
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PCA can be more informative when used in conjunction with treatments of a known
MoA. When these established treatments cluster with the treatment of interest, it indicates
that their mechanisms of action likely share the same target molecule or pathway. For this
study we used six HDPs with well-defined mechanisms of action: (i) magainin 2, a
membrane active HDP known to form toroidal pores in the membranes of both grampositive and gram-negative bacteria;21-23 (ii) buforin II, an HDP that binds to DNA after
crossing the cellular membrane of bacteria without damaging it;24-26 (iii) indolicidin, a nonlytic peptide with an internal target capable of creating pores in the inner and outer
membranes of gram-negative bacteria;9, 27 (iv) ixosin, an HDP that exerts its activity against
the membrane through oxidative damage utilizing bound Cu(II), resulting in membrane
perturbation28, 29; and (v-vi) piscidin 1 and 3 which have been shown to bind both the
membrane and DNA.30 Piscidin 1 interacts more strongly with the membrane, while
piscidin 3 interacts more strongly with DNA. Micrographs for each of the established HDPs
can be found in Figure 4-3.
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Figure 4-3
Representative micrographs of E. coli treated with (A) Buforin II, (B) Indolicidin, (C)
Ixosin, (D) Magainin 2, (E) Piscidin 1, and (F) Piscidin 3. Scale bars represent 5 μm.
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Based on the varied mechanisms of action presented above, it is no surprise that all
of our model peptides localize in different parts of the PCA plot, with the exception of
piscidin 1 and 3, which are found close together (Figure 4-2). ClavA Type A1 clusters with
indolicidin, indicating that Type A1 damage is likely similar to that inflicted by indolicidin.
ClavA Type N clusters with piscidin 1 and 3, as well as appearing near, but not clustering
with, magainin 2. This seems to indicate that while ClavA at neutral pH does interact with
the membrane, it is not forming pores as previously believed.1 In contrast with both Type
A1 and Type N, Type A2 does not cluster with any of the established peptide and instead
only clusters with ClavA-Zn(II), which serves to emphasize the uniqueness of the MoA
proposed for ClavA-Zn(II), and supports the observation that these mechanisms of action
are the same from the phenotypic analysis.
Membrane interaction studies reveal lack of pore formation in model membranes
While we have explored in detail the MoA of ClavA TypeA2, it is also important to
take a closer look at Type N and Type A1. Considering both of these have been described
previously by van Kan et al. as membrane based, and each clusters with HDPs that have
membrane activity as a part of their MoA, we decided to explore how ClavA interacts with
the membrane at pH 7.4 and 5.5.1 First, we performed circular dichroism (CD) spectroscopy
in the presence of lipid vesicles in order to study interaction of the peptide with the
membrane, the results of which are summarized in Table 4-4. These results show that the
peptide interacts strongly with the membrane at pH 5.5, achieving almost 100% helical
content at a peptide to lipid ratio of 1:80 (Figure 4-4A). Combined with the fact that Type
A1 clusters with indolicidin, this would seem to indicate that the MoA for Type A 1, and
likely the means by which ClavA enters bacterial cells, is similar to the membrane activity
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of indolicidin. The presence of Zn2+ appears to drastically reduce this interaction, as can be
seen by the 70% reduction in α-helical content. At pH 7.4, however, ClavA shows low alpha
helical content and largely inconsistent results across three trials (Figure 4-4B), which
seems to indicate breakdown of the lipid vesicles. This is somewhat consistent with findings
by van Kan et al. that, at neutral pH, ClavA causes more leakage of calcein than at 5.5.1
These results need to be explored further in order to draw meaningful conclusions, though
suffice it to say that the membrane interactions at pH 5.5 are much stronger than those at
7.4
Table 4-4
Percent α-helix formed by ClavA in the presence and absence of Zn(II) When exposed to
lipid vesicles
% Helical Content
P:L Ratio
pH 5.5

pH 5.5+Zn2+

pH 7.4

pH 7.4+Zn2+

1:0

9.59

-1.75

17.14

5.49

1:2

24.25

4.80

9.78

3.95

1:4

24.36

14.85

2.66

8.73

1:10

45.68

26.61

22.75

20.62

1:20

71.18

26.72

38.45

23.79

1:40

91.41

27.69

41.03

24.26

1:80

95.09

25.79

41.50

24.24

111

Figure 4-4
Circular Dichroism spectra of ClavA exposed to lipid vesicles at (A) pH 5.5, and (B) pH
7.4. Each line represents a different peptide to lipid ratio.

Many membrane active HDPs have been reported to form pores, especially magainin
2, while others, such as piscidin 1 and 3, can insert into the membrane and kill bacteria
without the formation of transmembrane pores. With this in mind, we next sought to
determine if nonmetallated ClavA behaves more like the former or the latter. The results of
X-ray diffraction experiments (Figure 4-5A) indicate that at pH 7.4, ClavA appears to
remain on the surface of the membrane, resulting in membrane thickening, which is in
direct contrast to the membrane thinning observed for magainin 2. 31 Additionally, Surface
Plasmon Resonance combined with Electrical Impedance Spectroscopy (SPR/EIS) indicate
that ClavA interaction with the membrane does not result in the formation of pores (Figure
4-5B and 4-5C). In fact, ClavA appears to increase the resistivity of the membrane, the
opposite effect of what would occur during pore formation. These results together indicate
that while ClavA may be interacting with the membrane, it is doing so in a way that is
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fundamentally different from either magainin 2 or the piscidins, though clustering with
piscidin 1 and 3 does indicate some similarity in target or activity. Further study of the
effect of ClavA interaction with bacterial membranes is necessary to fully understand what
is occurring in the Type N and Type A1 mechanisms.

Figure 4-5
(A) X-ray diffraction for POPC in the presence of ClavA. Lamellar diffraction from aligned
multilayers of POPC without (black) and with Clavanin A (red). There is an increase in the
repeat spacing with Clav A by roughly 1 Å, compared to POPC control. (B) Surface plasmon
resonance and electrical impedance spectroscopy of ClavA interacting with POPC were
measured simultaneously on a tethered bilayer membrane, at pH 7.4 and 5.5. At both pHs, the
changes in the SPR signal is negligible, indicative of weak or no adsorption of ClavA to the
bilayer. The increase in bilayer resistance seen in the EIS spectra may be due to superficial
peptide binding and occlusion of bilayer defects.
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4.3 – Discussion
We were also able to bridge the gap between our results, which show that ClavA
can act on DNA, resulting in growth inhibition, and the results first proposed by van Kan
and coworkers that provide evidence for ClavA as a membrane active peptide. 1 We
accomplished this through the utilization of BCP. As a means of studying mechanisms of
action, BCP has been utilized with small molecule antibiotics and anti-cancer
organometallic compounds, but never before has BCP been applied to the study of HDPs. 17,
20

Through the application of BCP we were able to determine that ClavA has at least three

different mechanisms of action which are dependent on pH and zinc concentration.
ClavA is not the first instance of a peptide for which the literature appears to
conflict regarding the MoA, especially when the apparent disagreement is between a
membrane-based MoA and an internal one. For example, indolicidin, upon first discovery
was believed to create membrane pores for its antimicrobial activity. 8 It was later
discovered that indolicidin can bind to DNA, interfering with replication, transcription, and
translation.9 It is likely that with varied treatment conditions, including incubation time and
peptide concentration, BCP would result in multiple phenotypes for indolicidin treated
cells, much like what we observed for ClavA. Another HDP for which the literature is
inconsistent is tachyplesin, which has been shown to target lipopolysaccharide, membrane
phospholipids, and the minor groove of DNA.10-13 Tachyplesin would be an excellent
candidate for study via BCP in the future to help pin down exactly what is happening during
the complicated HDP bacteria interaction. Piscidin 3 has been shown to be membranolytic,
as are many members of the piscidin family, and while it has been shown to have some
membrane-based activity, the MIC has been shown to be largely controlled by a DNA based
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MoA.14-16 This is further supported by the fact that while both appear close together in
Figure 4-2, piscidin 1 trends towards magainin 2, while piscidin 3 trends towards the DNA
active HDPs. In each of these cases, the application of BCP could streamline the process
of determining the MoA, though it is necessary to have a set of peptides with well-defined
and agreed upon mechanisms of action, such as buforin II and magainin 2, before this
method can be applied on a larger scale.
Together, the data presented in this study and the previous work on ClavA 1, 4 allow
us to propose the following as the most complete MoA for ClavA to date (Figure 4-6). At
neutral pH, ClavA exerts its activity by causing nonspecific membrane damage, likely
resulting in the loss of the proton motive force and the leakage of cellular contents (Type
N, Figure 4-6A). While this damage is not the result of the formation of membrane pores
(Figure 4-5B), this activity is supported by the clustering of Type N with the piscidins in
the PCA plot (Figure 4-2), the potential breakdown of lipid vesicles (Figure 4-4B), as well
as work performed by van Kan et al., which shows that at neutral pH, ClavA can dissipate
the transmembrane potential and can cause leakage of dyes from model membranes. 1 Based
on the elongated appearance of the cells treated at pH 7.4 (figure 4-1F), this activity appears
to inhibit the ability of E. coli to properly divide, a common MoA observed for several
classes of conventional antibiotics.17
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Figure 4-6
The MoA of ClavA (A) at neutral pH (Type N) involves membrane disruption (here
represented as the formation of a pore) as previously proposed1, (B and C) Type A1 at pH
5.5 which starts with the proposed binding of ClavA to ionophores, distorting their gating6
followed by indolicidin like DNA synthesis inhibition, and (D) Type A2 at pH 5.5 in which
ClavA-Zn(II) cleaves DNA as previously shown4. Orange helices represent ClavA; green
circles represent Zn(II) ions.
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When the pH is lowered to 5.5, as typically happens in phagosomes, the mechanism
changes to involve binding to membrane embedded ion channels, as presented by van Kan
and coworkers (Figure 4-6B).1, 4 Additionally, we have shown via CD that there is strong
membrane interaction at pH 5.5 (Figure 4-4A, Table 4-4), which could allow the
translocation of ClavA into the cytoplasm. Once there, ClavA binds to DNA and inhibits
DNA synthesis in a similar manner to indolicidin (Type A1, Figure 4-6C), which is
supported by Figure 4-2.
The interaction of ClavA with currently unidentified transmembrane ion channels
has some effect on their gating, allowing the free exchange of ions between the cytoplasm
and the extracellular space. It is this change to ion permeability that likely allows for an
increase in the intracellular Zn(II) concentration in bacteria (Figure 4-6B). ClavA, either
free floating or DNA bound, can bind to some of the newly increased concentration of
Zn(II) ions, allowing for subsequent DNA hydrolysis (Type A2, Figure 4-6D). Clavanins
were isolated from phagocytic cells of S. clava and postulated to be delivered into their
phagosomes when required.32-33 Although there are no reports on zinc ion trafficking inside
S. clava phagocytic cells, high micromolar concentrations of free zinc ions have been
shown to accumulate inside phagosomes of macrophages in response to certain bacterial
pathogens or stimuli.34-35 It is likely that the phagocytic cells in which the Clavanins are
found behave in a similar fashion to their murine and human counterparts. ClavA has also
been found in cytoplasmic granules, which are commonly secreted at the site of infection.33
In conditions outside of the Zn(II) enriched phagosome, ClavA would need to get Zn(II)
from the bacteria themselves, however, the free pool of zinc ions within a bacterium is low,
with most of the zinc bound within bacterial enzymes and virulence factors.36-37 One
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possible explanation for why ClavA exhibits these multiple mechanisms of action is that in
order to have free Zn(II) available to bind, ClavA needs to first kill some of the bacteria via
a different MoA, thereby increasing the local concentration of zinc ions.
Type A1 on its own would likely be only bacteriostatic, though this cannot be
observed because ClavA will eventually scavenge Zn(II) ions from the bacterium or
surrounding media, resulting in the Type A2 mechanism. This is supported by the
previously reported time kill kinetics data in which ClavA caused culture sterilization in 4
hr, while ClavA-Zn(II) accomplished the same feat in half the time.4 The potentiated
activity that is observed when Zn(II) is added to the culture medium comes from the
increased availability of those zinc ions. The proposed mechanisms also explain the 16fold decrease in MIC as normally ClavA needs to get inside and scavenge Zn(II) from the
bacterium.
As with all mechanistic studies on HDPs, it is important to note here that one MoA
cannot fully characterize the behavior of a population of HDPs. This has been shown
recently in a study utilizing bacterial spheroplasts to study the localization of buforin II and
magainin 2.38 In this work it is highly possible that in our low pH experiments, some small
percentage of the ClavA population may never transition from Type A1 to Type A2. It may
mean that the cells treated with that subset survive, or they may be killed through a yet
undiscovered mechanism.
4.4 – Methods
Bacterial Culture Conditions
Bacteria treated under low pH conditions were grown in LB media containing 50
mM MES buffer at pH 5.5. For the neutral pH experiments, bacteria were grown and treated in
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standard MHB media at pH 7.4. Cells were incubated at 37℃ and 234 rpm to mid-log phase
(OD600 = 0.4-0.6).
Confocal Fluorescence Microscopy
E. coli cultures were inoculated in culture media described above and grown to an OD600
of about 0.5 and treated with equal volumes of host defense peptides (HDPs) at a final
concentration of each peptide’s MIC value. These were incubated for one hour on a shaking
incubator at 37°C, followed by staining with 1 μg/mL FM 4-64, 2 μg/mL DAPI and 0.5 μM
SYTOX Green for 30 min. FM 4-64 selectively stains bacterial membranes while DAPI and
SYTOX Green both stain DNA and are cell permeable and impermeable, respectively.
These changes from the protocol by Nonejuie et al. were required because many HDPs
have been shown to completely sterilize cultures at timescales between one and two hours.
Additionally, with several of the HDPs tested few bacteria remained when treated with
concentrations of 5x MIC of the peptides.
After staining, the cultures were concentrated via centrifugation at 14000 rpm for 90 s,
and resuspended in 1/10 their original volume. Three microliters of the culture was then spotted
onto 1.5% agarose pads containing 20% LB medium, prepared using 65 μL gene frame seals on
microscope slides. The cells were then imaged using a Nikon A1R spectral confocal microscope
with a 60x oil immersion lens.
Bacterial Cytological Profiling
Bacterial Cytological Profiling (BCP) was performed using a procedure adapted from
Nonejuie et al.17 All cellular measurements were performed using ImageJ software, utilizing the
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freehand selection tool to trace either the membrane or nucleoid. Each was then measured for
area, perimeter, and circularity. Length and width were measured separately using the straightline selection tool. Average DAPI and SYTOX Green intensities were measured using the
outline of the membrane, and subtracted from the background intensity. The intensities were then
normalized against the intensities from untreated cells measured on the same day with the same
microscope and camera settings. In every case, measurements were made on at least 50 cells, and
every cell was measured in each image used, excluding any cells which we only partially
captured.
Principal Component Analysis
For each antimicrobial treatment, the cell morphology parameters were obtained
from at least three independent experiments. For each parameter, the average measurement
was also calculated and included in the dataset. The parameters were reduced into three
orthogonal variables using Principal Component Analysis (PCA) from our in-house Python
scripts. For each treatment, three cells were selected as representative cells by determining
three transformed measurements with the shortest Euclidean distance from the transformed
average measurement. The cell morphology parameters of the representative cells were
used for PCA of various group of treatments. Clustering was performed using the Euclidean
distance method from our in-house Python scripts, where centroids having distance of 2.4
units or lower are in the same cluster.
Circular Dichroism
CD spectroscopy was used to monitor titration of ClavA with 3:1 POPC/POPG
LUVs in phosphate buffer at pH 5.5 and pH 7.4. LUVs were prepared at both pHs as
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follows. Lipid films were made by mixing in a round bottom flask appropriate volumes of
POPC and POPG lipids solvated in chloroform. The chloroform was then evaporated
under a flow of nitrogen gas prior to lyophilization overnight. The dried lipid films were
hydrated with buffer (buffer concentration 2.5 mM, pH 5.5 or 5 mM, pH 7.4), producing
5 mM lipid suspensions. After several freeze-thaw cycles, the suspensions were extruded
using an Avanti Polar Lipids Mini Extruder, resulting in vesicles with a diameter of 200
nm. The LUV suspensions were then diluted to 2 mM, and the vesicles added to aqueous
ClavA (321.00 μM) and buffer to obtain samples with P:L ratios between 1:0 and 1:80,
each with a fixed peptide concentration of 20 µM. CD spectra were acquired by averaging
three scans collected at 293 K on a J-1500 spectrometer (Jasco Analytical Instruments,
Easton, MD) over a wavelength range of 190-260 nm using a scan speed of 100 nm/min
and a 1 nm bandwidth. Spectra for buffer and phospholipid blanks without peptide were
obtained and subtracted from the ClavA sample spectra to account for background signal.
Samples were made in triplicate using the same batch of LUVs. The molar ellipticity
obtained at 222 nm was converted into helicity, assuming an ellipticity of -32,000
deg·cm2/dmol for a perfect helix and -2000 deg·cm2/dmol for the fully disordered
peptide.39-40 Helicity was plotted in the form of a binding isotherm and fitted by a
nonlinear least-squares minimization in Microsoft Excel 2016 using the Solver Add-in.
Fit parameters included the binding constant, KD and the helical content of peptides in
the free and bound state. A binding stoichiometry of 1:1 between peptides and lipids was
used.
X-ray Diffraction Spectroscopy
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Clavanin A was incubated with preformed POPC lipid vesicles at a peptide to lipid
molar ration of 1:25. The solution was fused onto glass cover slips and bulk water was
allowed to evaporate slowly overnight at room temperature, producing aligned lipid
multilayers with incorporated peptide. Before diffraction experiments, the samples were
annealed at 98 % relative humidity and 30 C, for at least 12 h. X-ray diffraction
measurements were performed on a 3KW Rigaku Smartlab diffractometer located at the
Institute for Bioscience and Biotechnology Research (IBBR), Rockville, MD, as
described previously.41
Surface Plasmon Resonance/Electrical Impedance Spectroscopy
Tethered lipid bilayer membranes (tBLM) were prepared as described previously
using POPC lipid.42-43 The freshly prepared tBLM was stabilized in either TRIS buffer
(20 mM TRIS, 50 mM NaCl, pH=7.5) or MES buffer (50 mM MES, 50 mM NaCl, pH =
5.5) for SPR/EIS measurements at various pHs. Clavanin A was injected on top of the
preform tBLM in the corresponding buffer, at a concentration of 3 μM, allowed to
incubate with the bilayer for 10 minutes, followed by a buffer rinse. SPR/EIS spectra
were collected simultaneously, as a function of time, as described previously. 41
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Chapter 5 – Continuing the Narrative

“The important thing is not to stop questioning.”
-Albert Einstein, 1955
“I may not have gone where I intended to go, but I think I have ended up where I needed to be.”
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-Douglas Adams, The Long Dark Tea-Time of the Soul
5.1 – Future Directions and Newly Generated Questions
Most people believe that answers will follow logically from questions, but a good
scientist knows that this is not the case. For every scientist knows that as we gain answers, what
we really end up with is more questions. While this dissertation has answered many questions
about the antimicrobial activity of the tunicate HDP clavanin A, it also presents myriad questions
still in need of answers.
5.1.1 – The Clavanins
Despite the fact that the whole of this dissertation has been devoted to the study of
clavanin A, especially the zinc-based activity of clavanin A, there is still much more to
understand about this fascinating HDP. As alluded to at the end of chapter four, the previously
held beliefs regarding how clavanin A exerts its antimicrobial activity at pH 7.4 and 5.5 may not
be completely accurate, and more study of this topic will certainly uncover more information.1 In
chapters 2 and 3 the activity of clavanin A-Zn2+ was studied fairly thoroughly, and while we
were able to establish that His17 and His21 are important to that activity, it is not clear what the
role of His10 and His11 could be. Additionally, van Kan and coworkers were able to identify
that the abundant phenylalanine residues held importance for interaction with the membrane, but
nothing is known if those residues may play a role in the zinc based activity or interaction with
DNA.2 It is also unknown exactly how clavanin A is able to cross the membrane, knowledge
which will be important for the future development of antibiotics.
Little is known about the antimicrobial activity of clavanin B, though based on its high
degree of structural similarity to clavanin A (Table 1-1) it is likely that they will behave in a
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similar fashion. Preliminary data (Table 5-1) seems to indicate that this is the case, with the
activity of clavanin B improving 8-fold upon interaction with Zn2+. A comparison study between
clavanin A and clavanin B would provide interesting insight regarding the importance of
arginine versus lysine in the clavanins and in AMPs as a whole.
Table 5-1
Antimicrobial activities of the clavanins in the presence and absence of Zn 2+
Peptide

MIC without Zn2+

MIC with Zn2+

Clavanin A3

64 μM

4 μM

Clavanin B

64 μM

8 μM

Clavanin C

4 μM

4 μM

Clavanin D

2 μM

2 μM

Clavanin E

4 μM

4 μM

Clavaspirin

---

---

Clavanin C and clavanin D present some of the most interesting questions from the
family due to the presence of the DOPA residue in place of His17. This residue is capable of
crosslinking proteins, peptides, and DNA in a reaction catalyzed by Fe3+, which could result in
hitherto unexplored mechanisms of action for AMPs.4-6 DOPA is also capable of binding
divalent metal cations, though the results in Table 5-1 indicate that the addition of Zn2+ has no
effect on antimicrobial activity.6 It is possible, however, that metal chelators may reduce the
activity of these peptides. Additionally, the VFH ATCUN motif found in clavanin C has not
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been studied in detail, though preliminary results (Figure 5-1) show that it is Cu2+ binding,
making it likely that ROS formation is part of the activity of clavanin C.

Figure 5-1
(A) Isothermal titration calorimetry data for the binding of clavanin C to Cu2+ in MES
buffer, pH 5.5. (B) Mass spectrometry showing copper bound clavanin C.

Clavanin E and Clavaspirin remain the biggest mysteries of the clavanin family. Both of
these HDPs have received minimal attention, and their most defining feature is that they were
discovered as a result of studying the DNA of S. clava.7-8 Clavanin E is particularly interesting
due to the fact that despite having the exact same configuration of histidine residues as clavanin
A and clavanin B (Table 1-1), clavanin E shows no improvement upon addition of Zn2+. This
may indicate that a different metal is important to the antimicrobial activity of clavanin E, or
some feature of its structure keeps the improvement seen in clavanin A and clavanin B from
occurring. Despite its drastic difference in sequence from the other clavanins, Clavaspirin has
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two HX3H motifs, which strengthens the argument that this is an important motif, as well as
presenting the possibility for Clavaspirin to bind Zn2+ or some other metal ion with biological
relevance to S. clava.
5.1.2 – Clavanin Synergy
All six clavanins are produced by the same cells in S. clava by genes in the same region
of the genome. It stands to reason that if an organism as simple as S. clava was able to evolve
one or two effective antimicrobial compounds it would not waste genetic space and valuable
resources to produce six related compounds. This line of thought leads to the question: Is there a
reason S. clava produces so many related antimicrobial peptides? One possible answer to this
question is the idea that some members of the clavanin family may be synergistic with one
another. Synergy among AMPs is widely sought after as a means of creating drug cocktails
which are not only effective, but also limit the ability of bacteria to develop antibiotic resistance.
To date only a small handful of AMP pairs have been identified that behave synergistically.
Synergy can be quantified by calculating the fractional inhibitory concentration (FIC) for
a pair of antimicrobials using the following formula:

𝐹𝐼𝐶 =

𝑀𝐼𝐶[𝐴] 𝑀𝐼𝐶[𝐵]
+
𝑀𝐼𝐶𝐴
𝑀𝐼𝐶𝐵

where MICA and MICB are the MIC values for AMP A and AMP B alone, and MIC[A] and
MIC[B] are the MICs of each component when in a mixture. FIC values less than or equal to 0.5
represent a 4-fold activity increase for each AMP, indicating synergy. While FIC can be most
accurately obtained by measuring a wide range of different concentration combinations in a
checkerboard assay, looking at one to one mixtures can provide a reasonable approximation. For
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the clavanins (excluding Clavaspirin) synergy in one to one mixtures can only be observed for
clavanin A and clavanin B (Table 5-2), while the other combinations can be described as additive
or indifferent. It still remains to be seen how Clavaspirin factors in to the synergism among the
clavanins, though potential synergy may explain the drastic difference between Clavaspirin and
the other clavanins. It is also possible that there may be synergy with mixtures of three or more
clavanins, though those conditions still need to be explored.
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Table 5-2
Summary of synergy testing on 1:1 mixtures of clavanins A-E
Peptide

MICpeptide 1

MICpeptide 2

MICmixture

FIC

Definition a

A+B

64 μM

64 μM

16 μM

0.25

Synergy

A+C

64 μM

4 μM

8 μM

1.0625

Indifferent

A+D

64 μM

2 μM

4 μM

1.03125

Indifferent

A+E

64 μM

4 μM

4 μM

0.53125

Additive

B+C

64 μM

4 μM

8 μM

1.0625

Indifferent

B+D

64 μM

2 μM

4 μM

1.03125

Indifferent

B+E

64 μM

4 μM

4 μM

0.53125

Additive

C+D

4 μM

2 μM

4 μM

1.5

Indifferent

C+E

4 μM

4 μM

4 μM

1.0

Additive

D+E

2 μM

4 μM

4 μM

1.5

Indifferent

a Synergy = FIC≤0.5, Additive = 0.5<FIC≤1.0, Indifferent = 1.0<FIC≤4.0,
Antagonism = FIC>4.0
5.1.3 – Expanding the Utility of Bacterial Cytological Profiling
In chapter 4, BCP was utilized for the first time for the identification of the mechanism of
action of an AMP. While this proof of concept is an excellent first step toward wide-spread use
of this technique for the study of AMPs, there is still much that need to be done in order for this
to come to fruition. One of the biggest hurdles that needs to be overcome is the overall lack of
data for AMPs in BCP. Since this is a relatively new technique for the field, it is important to
study as many AMPs as possible with BCP in order to establish trends for future use. The work
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done in chapter 4 with magainin 2, indolicidin, buforin II, ixosin, piscidin 1, and piscidin 3 is
certainly a strong start, however, further application of this technique will certainly lead to better
data and faster mechanism of action determination for many newly identified or synthesized
AMPs.
Despite the obvious need for more groundwork, BCP can still have utility for studying
the clavanin family of HDPs. One of the possible questions mentioned above is why S. clava
would waste precious resources producing six antimicrobial compounds when one or two of the
more potent examples would suffice. While synergy may be one possible answer to this question,
another could be discovered through application of BCP. Preliminary results, summarized in
Figure 5-2, Table 5-3 and Table 5-4, show that the clavanins have a wide range of activities.
Additionally, clavanin B has at least two different mechanisms of action, much like clavanin A,
though while one appears very close to clavanin A Type A1, the other is quite different from
anything seen for the other clavanins. It is possible, given these preliminary results, that other
clavanins will have multiple mechanisms of action under particular conditions, which may lead
to a greater understanding of why all of these closely related HDPs would be produced.
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Figure 5-2
Three dimensional PCA plot showcasing preliminary findings on the clavanin family of
HDPs.
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Table 5-3
Average morphology measurements of clavanin treated bacterial membranes
Area

Perimeter

Length

Width

(μm2)

(μm)

(μm)

(μm)

3.787

8.532

3.287

1.239

0.658

1.333

3.272

7.933

2.961

1.072

0.667

1.229

5.557

11.336

4.641

1.278

0.550

1.873

3.443

7.574

2.823

1.173

0.752

1.063

4.513

9.260

3.471

1.410

0.660

1.667

4.015

8.822

3.116

1.199

0.652

1.364

Clavanin C

3.932

8.963

3.320

1.157

0.623

1.469

Clavanin D

4.116

9.660

3.736

1.155

0.569

1.652

Clavanin E

5.314

11.141

4.359

1.180

0.557

1.704

Treatment

Nucleoids/
Circularity
Cell

Clavanin A
Type A1
Clavanin A
Type A2
Clavanin A
Type N
ClavAZn(II)
Clavanin B
Type 1
Clavanin B
Type 2
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Table 5-4
Average morphology measurements of clavanin treated bacterial nucleoids

Area

Perimeter

Length

Circularity
(μm )

(μm)

(μm)

Corrected

SYTOX

DAPI

Intensity

Intensity

Width

Treatment
2

Corrected
(μm)

Clavanin A
1.288

4.845

1.967

0.693

0.677

1.285

2.869

1.746

5.641

2.083

0.845

0.688

15.165

3.626

1.425

5.068

1.919

0.775

0.701

1.005

0.842

2.476

6.643

2.480

0.945

0.702

15.644

2.430

1.128

4.400

1.510

0.697

0.736

1.061

2.126

0.799

3.531

1.110

0.811

0.806

8.862

5.264

Clavanin C

1.254

4.753

1.496

0.715

0.697

1.065

1.126

Clavanin D

1.236

4.631

1.612

0.765

0.726

1.040

1.311

Clavanin E

1.829

5.837

2.094

0.849

0.682

0.997

1.335

Type A1
Clavanin A
Type A2
Clavanin A
Type N
ClavAZn(II)
Clavanin B
Type 1
Clavanin B
Type 2
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5.2 – Conclusions
The results presented in this dissertation serve to elucidate how much we still have to
learn about HDPs. Prior to our first study, clavanin A appeared in ten publications which showed
that it was a membrane active HDP. Despite this, we were able to discover a new mechanism of
action for clavanin A when bound to Zn2+, a mechanism of action that is novel for zinc-binding
AMPs. Results such as these are vital for the future, as these discoveries will pave the way
toward peptide based antimicrobials that will, one day, stem the ever growing scourge of
antibiotic resistant bacteria.
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